1. Introduction
===============

The resistance of Gram-negative and Gram-positive organisms to antimicrobial agents has been widely documented in Europe. The recent report of the European Centre for Disease Prevention and Control (ECDC) included data from 35 Italian hospitals, most of whom used the Clinical and Standards Institute (CLSI) guidelines \[[@B1-pharmaceuticals-06-01381]\], and it showed that Italy had experienced decreased vancomycin resistance in *Enterococcus faecium* and reduced penicillin non-susceptibility in *Streptococcus pneumoniae* between 2007 and 2011. There were also stable proportions of methicillin-resistant *Staphylococcus aureus* (MRSA) (33--40%), high-level aminoglycoside-resistant *Enterococcus faecalis* (36--50%) and a sudden increase of carbapenem-resistant *Klebsiella pneumoniae* (from 1% in 2006 to 27% in 2011) in Italy during this time.

Among the different surveillance studies run globally, the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), which has been ongoing since 2004, was initiated to monitor continuously the antibacterial activity of tigecycline and to compare its potency with those of other antimicrobials used in therapy. Tigecycline is the first member of the glycylcycline family of antimicrobials to be administered for bacterial infections. This agent has demonstrated activity against key resistant Gram-negative and Gram-positive phenotypes, both *in vitro* and *in vivo* \[[@B2-pharmaceuticals-06-01381]\]. This paper will describe the antimicrobial susceptibilities of several important Gram-negative and Gram-positive pathogens, collected in Italy as a part of T.E.S.T., to a range of antimicrobial agents between 2004 and 2011.

2. Materials and Methods
========================

2.1. Isolate Collection
-----------------------

A total of 27 centres in Italy collected isolates for T.E.S.T. between 2004 and 2011 (2004, six centres; 2005, eight; 2006, 15; 2007, 13; 2008, 17; 2009, 13; 2010, 13; and 2011, 12 centres). A minimum of 135 Gram-negative isolates were required to be submitted by each centre, including 15 *Acinetobacter* spp., 25 *Enterobacter* spp., 25 *Escherichia coli*, 15 *Haemophilus influenzae*, 25 *Klebsiella* spp. (*K. oxytoca* and *K. pneumoniae*), 20 *Pseudomonas aeruginosa*, and 10 *Serratia* spp. All isolates were drawn from samples collected for diagnosis purposes. Isolates of *Enterobacter* spp., *E. coli* and *Klebsiella* spp. were tested for extended-spectrum β-lactamase (ESBL) production. Isolates of *H. influenzae* were tested for β-lactamase (BL) production. Each centre in Italy was also obliged to collect a minimum of 65 Gram-positive isolates, consisting of 15 *Enterococcus* spp. (*E. faecium* and *E. faecalis*), 25 *S. aureus*, 10 *Streptococcus agalactiae*, and 15 *S. pneumoniae*. All body sites were accepted sources of clinical isolates, however, no more than 25% of isolates could be urinary. Only one isolate from each patient could be included in the study, and the participant's medical history, antimicrobial use, age and gender were not considered.

2.2. Antimicrobial Susceptibility Testing
-----------------------------------------

Each participating T.E.S.T. centre was responsible for the initial identification and susceptibility testing of all isolates collected. The minimum inhibitory concentrations (MICs) for each T.E.S.T. agent and pathogen were determined using CLSI broth microdilution methodology \[[@B3-pharmaceuticals-06-01381]\] and either MicroScan^®^ panels (Dade Microscan Inc., West Sacramento, CA, USA) or Sensititre^®^ plates (TREK Diagnostic Systems, East Grinstead, UK), both of which are compatible with CLSI methodology \[[@B4-pharmaceuticals-06-01381]\]. The antimicrobial agents that formed the core T.E.S.T. panel for all organisms were: amoxicillin-clavulanate (AMC), ampicillin (AMP), ceftriaxone (CRO), imipenem (IPM), levofloxacin (LVX), meropenem (MEM), minocycline (MIN), piperacillin-tazobactam (TZP) and tigecycline (TGC). Due to reliability and quality control issues with MicroScan^®^ plates containing imipenem, their use was discontinued in 2006 in favour of Sensititre^®^ plates containing meropenem.

Gram-negative pathogens were tested against the core T.E.S.T. agents, plus amikacin (AMK) and cefepime (FEP). Isolates of *A. baumannii* and *P. aeruginosa* were also tested against ceftazidime (CAZ). Gram-positive isolates were tested against linezolid (LZD), penicillin (PEN) and vancomycin (VAN) in addition to the core panel of agents. As well as these, *S. pneumoniae* isolates were tested against the macrolides (azithromycin \[AZM\], clarithromycin \[CLR\] and erythromycin \[ERY\]) plus clindamycin (CLI). The following quality control Gram-negative and Gram-positive strains were tested on each day of isolate testing: *E. coli* ATCC 25922, *H. influenzae* ATCC 49247 and ATCC 49766, *P. aeruginosa* ATCC 27853, *E. faecalis* ATCC 29212, *S. aureus* ATCC 29213, and *S. pneumoniae* ATCC 49619. MIC~90~ data were included in this manuscript only if the daily quality control (QC) test results were within the acceptable range published by the CLSI \[[@B5-pharmaceuticals-06-01381]\].

After identification and determination of antimicrobial MICs at each T.E.S.T. centre, isolates were sent to a central laboratory, Laboratories International for Microbiology Studies, which is a division of International Health Management Associates, Inc. (IHMA, Schaumburg, IL, USA). The central laboratory organised the transport of isolates from all centres, as well as the storage of isolates. IHMA also performed QC checks on approximately 10% of isolates, which included verification of identification as well as susceptibility testing.

Antimicrobial susceptibility was reported using CLSI breakpoints \[[@B5-pharmaceuticals-06-01381]\]. For *Enterobacter* spp., the carbapenem breakpoints were revised in 2010 \[[@B6-pharmaceuticals-06-01381]\]. For tigecycline, the breakpoints as approved by the US Food and Drug Administration in the tigecycline package insert were used in this analysis \[[@B7-pharmaceuticals-06-01381]\]. As *Acinetobacter* and *Pseudomonas* are not among the organisms listed under the approved clinical indications in the tigecycline prescribing information, no tigecycline breakpoints are available for these organisms \[[@B7-pharmaceuticals-06-01381]\]. Multidrug resistance (MDR) has previously been defined in numerous different ways \[[@B8-pharmaceuticals-06-01381],[@B9-pharmaceuticals-06-01381],[@B10-pharmaceuticals-06-01381]\], particularly for *P. aeruginosa* and *A. baumannii*; in the current study, as in previous T.E.S.T. reports, MDR is defined as resistance to three or more classes of agents on the T.E.S.T. panel. The class definitions and corresponding agents used in this analysis were aminoglycosides (amikacin), β-lactams (cefepime, ceftazidime, ceftriaxone, or piperacillin-tazobactam), carbapenems (imipenem or meropenem), fluoroquinolones (levofloxacin), and tetracyclines (minocycline). Intermediate resistant isolates were not included in the resistant category in this report.

3. Results
==========

A total of 13,245 isolates were submitted from Italian medical centres for T.E.S.T. between 2004 and 2011. Of these, 9,167 (69.2%) isolates were Gram-negative ([Table 1](#pharmaceuticals-06-01381-t001){ref-type="table"} and [Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}) and 4,078 (30.8%) isolates were Gram-positive ([Table 1](#pharmaceuticals-06-01381-t001){ref-type="table"} and [Table 3](#pharmaceuticals-06-01381-t003){ref-type="table"}). Imipenem results are available only between 2004 and 2006, thus cannot be discussed in longitudinal terms in this study.

3.1. Gram-Negative Isolates
---------------------------

The majority of Gram-negative isolates were *E. coli* (21.1%), followed by *Enterobacter* spp. (18.9%), *P. aeruginosa* (16.0%), *K. pneumoniae* (15.2%), *A. baumannii* (9.6%), *H. influenzae* (8.1%), *S. marcescens* (7.1%), and *K. oxytoca* (4.1%; [Table 1](#pharmaceuticals-06-01381-t001){ref-type="table"}). In broad terms, tigecycline, the carbapenems and amikacin were active against most Gram-negative pathogens in Italy during the study period.

### 3.1.1. *A.* *baumannii*

No breakpoints were available for tigecycline, although the lowest overall MIC~90~ was observed for tigecycline (2 mg/L; [Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}). *A. baumannii* were most susceptible to minocycline with 81.0% susceptibility over all study years combined. Isolates of *A. baumannii* from Italy had low susceptibility (\<40%) to most of the remaining T.E.S.T. panel agents: amikacin, cefepime, ceftazidime, ceftriaxone, levofloxacin, meropenem and piperacillin-tazobactam. The susceptibility of isolates to amikacin, cefepime, ceftazidime, ceftriaxone and levofloxacin all increased in 2005 before declining again from 2006 to 2011. From 2006 onwards, there was an overall increase in the resistance of *A. baumannii* isolates to amikacin, cefepime, ceftazidime, ceftriaxone, levofloxacin, and piperacillin-tazobactam ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}). Very few *A. baumannii* isolates (\<1%) were resistant to minocycline between 2004 and 2007, but this percentage rose to 7.9% and 7.6%, respectively, in 2009 and 2010 before decreasing to 2.5% in 2011. A total of 526 MDR *A. baumannii* isolates were collected in Italy during T.E.S.T. ([Table 4](#pharmaceuticals-06-01381-t004){ref-type="table"}), which represented 60.0% of all *A. baumannii* isolates. Over the surveillance period, MDR *A. baumannii* isolates had ≥79.5% resistance to all agents tested with the exception of minocycline (5.1%). Among *A. baumannii*, 79.7% were susceptible to imipenem ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}) while 49.0% of MDR isolates were susceptible to imipenem ([Table 4](#pharmaceuticals-06-01381-t004){ref-type="table"}).

### 3.1.2. *Enterobacter* spp.

Isolates of *Enterobacter* spp. were \>90% susceptible to amikacin, cefepime, meropenem and tigecycline during T.E.S.T. ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}). Susceptibility to minocycline almost halved between 2005 and 2009 (from 85.8% to 49.8%), then doubled again to 82.8% in 2011. Almost 50% of isolates were resistant to ceftriaxone over all T.E.S.T. years combined, with the highest resistance recorded in 2004 (64.8%) and the lowest in 2011 (26.3%). The lowest resistance over all T.E.S.T. years was to tigecycline (0.9%). Among *Enterobacter* isolates, 86.9% were susceptible to imipenem between 2004 and 2006 ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}).

pharmaceuticals-06-01381-t001_Table 1

###### 

Numbers of Gram-negative and Gram-positive isolates collected in Italy during Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004--2011.

  Organism                 2004           2005            2006              2007            2008   2009   2010   2011   2004--2011
  ------------------------ -------------- --------------- ----------------- --------------- ------ ------ ------ ------ --------------------
  *A. baumannii*           47 (46/1)      51 (46/5)       116 (61/55)       77              193    127    145    121    877 (153/724)
  *Enterobacter* spp       91 (89/2)      120 (113/7)     252 (156/96)      176             391    213    276    209    1728 (358/1370)
  *E. coli*                91 (89/2)      139 (138/1)     254 (148/106)     190             432    252    285    288    1931 (375/1556)
  *H. influenzae*          45 (44/1)      71 (48/23)      109 (71/38)       75              155    115    80     89     739 (163/576)
  *K. oxytoca*             16 (14/2)      29              67 (42/25)        46              73     69     41     39     380 (85/295)
  *K. pneumoniae*          77 (74/3)      86 (80/6)       191 (117/74)      127             329    200    225    160    1395 (271/1124)
  *P. aeruginosa*          72 (70/2)      103 (97/6)      186 (111/75)      144 (1/143)     352    188    222    202    1469 (279/1190)
  *S. marcescens*          42 (38/4)      42 (38/4)       90 (50/40)        67              140    75     95     97     648 (126/522)
  **Total**                481 (464/17)   641 (589/52)    1265 (756/509)    902 (1/901)     2065   1239   1369   1205   9167 (1810/7357)
  **Gram-positive**                                                                                                     
  *E. faecalis*            32 (29/3)      52 (42/10)      106 (55/51)       84              132    92     115    127    740 (126/614)
  *E. faecium*             22 (20/2)      16 (11/5)       40 (26/14)        19              103    50     45     41     336 (57/279)
  *S. aureus*              91 (83/8)      113 (100/13)    217 (89/128)      187             376    224    278    234    1720 (272/1448)
  *S. agalactiae*          36             40 (21/19)      91 (38/53)        72              133    76     106    58     612 (95/517)
  *S. pneumoniae*          41 (15/26)     65 (48/17)      111 (59/52)       84              143    105    92     29     670 (122/548)
  **Total**                222 (183/39)   286 (222/64)    565 (267/298)     446             887    547    636    489    4078 (672/3406)
  **All Isolates Total**   703 (647/56)   927 (811/116)   1830 (1023/807)   1348 (1/1347)   2952   1786   2005   1694   13245 (2482/10763)

N = total number of isolates; values given in parentheses refer to the number of isolates tested against imipenem and meropenem, respectively; where no parentheses are given, all isolates were tested against imipenem (2004--2006) or meropenem (2007--2011).

pharmaceuticals-06-01381-t002_Table 2

###### 

Minimum inhibitory concentration (MIC)~90~ (mg/L), antimicrobial susceptibility (%S), and antimicrobial resistance (%R) for Gram-negative isolates collected in Italy during T.E.S.T. 2004--2011.

  Organism              Agent^a^   2004    2005   2006   2007   2008   2009   2010    2011   2004--2011                                                                                                                                
  --------------------- ---------- ------- ------ ------ ------ ------ ------ ------- ------ ------------ ------- ------ ------ ------- ------ ------ ------- ------ ------ ------- ------ ------ ------- ------ ------ ------- ------ ------
  *A. baumannii*        TGC        1       NA     NA     1      NA     NA     2       NA     NA           1       NA     NA     2       NA     NA     2       NA     NA     2       NA     NA     1       NA     NA     2       NA     NA
                        AMP        ≥64     NA     NA     ≥64    NA     NA     ≥64     NA     NA           ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA
                        AMC        ≥64     NA     NA     ≥64    NA     NA     ≥64     NA     NA           ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA
                        TZP        ≥256    63.8   31.9   ≥256   60.8   29.4   ≥256    29.3   55.2         ≥256    39.0   57.1   ≥256    29.5   63.7   ≥256    27.6   67.7   ≥256    20.0   75.9   ≥256    17.4   81.0   ≥256    30.4   63.3
                        CAZ        ≥64     42.6   53.2   ≥64    52.9   41.2   ≥64     23.3   71.6         ≥64     39.0   59.7   ≥64     30.6   65.3   ≥64     26.0   70.9   ≥64     18.6   75.2   32      20.7   75.2   ≥64     28.3   67.4
                        CRO        ≥128    25.5   53.2   ≥128   39.2   35.3   ≥128    16.4   75.9         ≥128    33.8   59.7   ≥128    18.7   70.5   ≥128    18.1   73.2   ≥128    13.8   77.9   64      15.7   74.4   ≥128    20.0   69.4
                        FEP        ≥64     40.4   36.2   32     49.0   27.5   ≥64     24.1   57.8         ≥64     40.3   53.2   ≥64     32.6   57.5   ≥64     35.4   51.2   ≥64     26.2   60.0   ≥64     18.2   63.6   ≥64     30.9   54.6
                        IPM        ≥32     82.6   17.4   8      82.6   8.7    16      75.4   14.8         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     16      79.7   13.7
                        MEM        \-      \-     \-     \-     \-     \-     ≥32     30.9   47.3         16      63.6   28.6   ≥32     48.7   37.3   ≥32     36.2   53.5   ≥32     25.5   69.0   ≥32     19.0   79.3   ≥32     36.9   53.6
                        LVX        ≥16     53.2   40.4   ≥16    60.8   27.5   ≥16     25.0   63.8         ≥16     36.4   55.8   ≥16     30.6   66.3   ≥16     26.8   69.3   ≥16     20.0   76.6   ≥16     15.7   84.3   ≥16     29.0   66.0
                        AMK        ≥128    55.3   31.9   64     76.5   21.6   ≥128    43.1   49.1         ≥128    42.9   54.5   ≥128    43.0   51.8   ≥128    30.7   65.4   ≥128    37.2   60.0   ≥128    20.7   73.6   ≥128    39.8   55.2
                        MIN        2       100    0.0    1      96.1   0.0    2       96.6   0.9          1       100    0.0    8       88.6   2.1    8       71.7   7.9    8       55.2   7.6    8       68.6   2.5    8       81.0   3.3
  *Enterobacter* spp.   TGC        4       87.9   2.2    2      97.5   0.8    4       86.5   2.0          1       97.7   0.0    2       96.7   0.3    2       94.4   1.9    2       95.7   1.1    1       99.0   0.0    2       94.7   0.9
                        AMP        ≥64     0.0    95.6   ≥64    0.8    94.2   ≥64     0.0    94.0         ≥64     1.2    91.8   ≥64     2.8    88.2   ≥64     5.2    83.6   ≥64     1.5    85.1   ≥64     1.4    86.1   ≥64     1.9    88.9
                        AMC        ≥64     6.6    90.1   ≥64    4.2    94.2   ≥64     2.4    95.2         ≥64     5.1    86.4   ≥64     3.6    92.3   ≥64     5.6    92.0   ≥64     2.5    95.3   ≥64     2.4    96.2   ≥64     3.7    93.1
                        TZP        ≥256    58.2   31.9   128    63.3   17.5   ≥256    62.3   23.0         ≥256    65.9   23.3   ≥256    63.9   25.1   ≥256    62.4   23.0   ≥256    60.5   23.9   64      82.3   9.6    ≥256    65.0   22.1
                        CRO        ≥128    29.7   64.8   ≥128   45.8   52.5   ≥128    49.2   48.0         ≥128    55.7   39.8   ≥128    49.6   48.6   ≥128    52.1   45.5   ≥128    50.0   47.5   64      70.3   26.3   ≥128    51.7   45.5
                        FEP        ≥64     75.8   16.5   8      93.3   4.2    16      86.9   8.7          8       90.3   8.0    8       91.6   6.1    8       92.5   5.2    16      88.4   9.1    4       94.7   2.9    8       90.0   7.1
                        IPM        2       79.8   3.4    4      80.5   10.6   1       95.5   3.9          \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     2       86.9   5.9
                        MEM        \-      \-     \-     \-     \-     \-     1       93.8   6.3          0.5     96.0   2.3    0.5     95.9   2.8    0.25    98.1   1.9    0.5     96.7   1.8    0.12    99.0   0.5    0.5     96.6   2.4
                        LVX        ≥16     64.8   31.9   ≥16    75.0   24.2   ≥16     75.4   22.2         ≥16     77.3   22.2   ≥16     77.0   22.0   ≥16     82.6   16.0   ≥16     76.1   23.2   2       90.9   7.7    ≥16     78.2   20.4
                        AMK        16      95.6   0.0    8      95.8   2.5    8       96.4   3.2          4       97.2   1.1    8       95.9   1.5    2       97.7   2.4    4       98.6   0.7    4       99.0   0.0    8       97.1   1.5
                        MIN        16      68.1   12.1   8      85.8   5.8    16      78.2   11.9         16      75.6   10.8   16      68.5   12.5   16      49.8   13.6   16      51.8   19.2   8       82.8   5.7    16      68.6   12.2
  *E. coli*             TGC        0.5     100    0.0    0.5    100    0.0    0.5     100    0.0          0.5     100    0.0    0.5     100    0.0    0.5     99.6   0.0    1       100    0.0    0.5     100    0.0    0.5     99.9   0.0
                        AMP        ≥64     29.7   70.3   ≥64    46.8   53.2   ≥64     30.3   68.5         ≥64     35.8   63.7   ≥64     23.6   75.7   ≥64     27.0   71.0   ≥64     22.8   76.8   ≥64     26.7   72.2   ≥64     28.4   70.7
                        AMC        32      53.8   27.5   32     72.7   12.2   32      62.2   13.4         16      65.8   8.4    32      54.4   18.8   32      52.8   22.6   32      48.1   21.4   32      71.9   10.4   32      59.3   16.6
                        TZP        128     83.5   13.2   64     87.1   8.6    32      89.0   5.1          16      92.1   2.6    64      82.2   8.6    128     77.8   11.5   128     78.2   10.5   32      88.9   6.6    64      84.3   8.1
                        CRO        64      79.1   18.7   ≥128   81.3   17.3   ≥128    76.0   22.8         ≥128    83.2   16.8   ≥128    63.4   35.6   ≥128    58.7   39.3   ≥128    57.5   41.8   64      64.6   34.4   ≥128    67.7   31.2
                        FEP        8       93.4   4.4    32     87.1   11.5   16      88.6   7.9          32      85.3   12.6   ≥64     77.8   17.4   ≥64     74.2   23.8   ≥64     72.3   20.4   ≥64     77.4   16.3   ≥64     80.0   15.7
                        IPM        0.5     100    0.0    0.5    100    0.0    0.25    98.6   0.0          \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     0.5     99.5   0.0
                        MEM        \-      \-     \-     \-     \-     \-     ≤0.06   99.1   0.9          ≤0.06   100    0.0    ≤0.06   97.9   1.2    ≤0.06   98.4   0.4    ≤0.06   99.6   0.4    ≤0.06   100    0.0    ≤0.06   99.0   0.5
                        LVX        ≥16     63.7   33.0   ≥16    67.6   30.2   ≥16     57.5   39.8         ≥16     63.7   33.7   ≥16     46.1   51.4   ≥16     52.0   47.2   ≥16     42.1   56.1   ≥16     50.3   43.8   ≥16     52.5   44.7
                        AMK        8       100    0.0    16     94.2   3.6    8       98.4   0.8          8       98.9   0.5    8       96.3   2.3    8       96.8   1.2    8       98.2   0.4    8       99.0   0.0    8       97.6   1.1
                        MIN        ≥32     70.3   23.1   16     77.7   10.8   16      69.3   19.7         16      73.7   13.2   16      74.5   16.0   ≥32     70.2   19.0   16      62.8   20.0   16      81.9   10.8   16      72.6   16.4
  *H. influenzae*       TGC        0.25    100    NA     0.25   98.6   NA     0.25    94.5   NA           0.25    92.0   NA     0.25    99.4   NA     0.25    100    NA     0.25    97.5   NA     0.25    100    NA     0.25    97.8   NA
                        AMP        2       88.9   8.9    16     81.7   14.1   2       87.2   9.2          16      84.0   14.7   8       84.5   14.2   ≤0.5    96.5   2.6    32      85.0   15.0   1       91.0   6.7    4       87.6   10.6
                        AMC        1       100    0.0    2      95.8   4.2    1       100    0.0          1       100    0.0    1       100    0.0    1       100    0.0    2       100    0.0    1       100    0.0    1       99.6   0.4
                        TZP        ≤0.06   100    0.0    0.12   98.6   1.4    ≤0.06   99.1   0.9          ≤0.06   100    0.0    ≤0.06   100    0.0    ≤0.06   100    0.0    ≤0.06   100    0.0    ≤0.06   100    0.0    ≤0.06   99.7   0.3
                        CRO        ≤0.06   100    NA     0.12   98.6   NA     ≤0.06   100    NA           0.12    100    NA     ≤0.06   100    NA     ≤0.06   100    NA     ≤0.06   100    NA     ≤0.06   100    NA     ≤0.06   99.9   NA
                        FEP        ≤0.5    100    NA     ≤0.5   98.6   NA     ≤0.5    100    NA           ≤0.5    94.7   NA     ≤0.5    99.4   NA     ≤0.5    100    NA     ≤0.5    100    NA     ≤0.5    98.9   NA     ≤0.5    99.1   NA
                        IPM        1       100    NA     1      100    NA     0.5     100    NA           \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     1       100    NA
                        MEM        \-      \-     \-     0.25   100    NA     0.12    100    NA           0.12    100    NA     0.25    100    NA     0.12    100    NA     0.12    100    NA     0.25    100    NA     0.12    100    NA
                        LVX        0.015   100    NA     0.12   100    NA     0.03    100    NA           0.03    100    NA     0.03    100    NA     0.015   100    NA     0.03    100    NA     0.03    100    NA     0.03    100    NA
                        AMK        8       NA     NA     8      NA     NA     8       NA     NA           8       NA     NA     8       NA     NA     8       NA     NA     8       NA     NA     8       NA     NA     8       NA     NA
                        MIN        1       97.8   2.2    2      94.4   0.0    1       99.1   0.0          1       98.7   0.0    2       98.7   0.0    1       99.1   0.9    1       100    0.0    1       95.5   2.3    1       98.1   0.5
  *K. oxytoca*          TGC        \-      \-     \-     2      96.6   0.0    1       97.0   0.0          1       97.8   0.0    0.5     98.6   0.0    1       97.1   0.0    1       95.1   0.0    0.5     100    0.0    1       97.4   0.0
                        AMP        \-      \-     \-     ≥64    0.0    100    ≥64     0.0    92.5         ≥64     2.2    89.1   ≥64     1.4    87.7   ≥64     2.9    82.6   ≥64     2.4    87.8   ≥64     15.4   64.1   ≥64     2.9    86.3
                        AMC        \-      \-     \-     16     75.9   6.9    32      77.6   13.4         32      80.4   13.0   32      71.2   12.3   32      73.9   17.4   16      85.4   9.8    4       92.3   5.1    32      77.1   13.2
                        TZP        \-      \-     \-     ≥256   82.8   13.8   ≥256    85.1   14.9         4       95.7   4.4    ≥256    79.5   17.8   ≥256    82.6   15.9   8       90.2   9.8    8       94.9   5.1    ≥256    85.0   13.9
                        CRO        \-      \-     \-     8      82.8   13.8   8       85.1   11.9         0.5     93.5   6.5    32      76.7   21.9   16      73.9   24.6   16      87.8   12.2   0.25    100    0.0    8       82.6   16.1
                        FEP        \-      \-     \-     2      93.1   6.9    4       97.0   1.5          ≤0.5    100    0.0    8       95.9   2.7    4       95.7   1.5    ≤0.5    97.6   2.4    ≤0.5    100    0.0    2       97.1   1.8
                        IPM        \-      \-     \-     0.5    100    0.0    0.5     100    0.0          \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     0.5     98.8   0.0
                        MEM        \-      \-     \-     \-     \-     \-     0.12    100    0.0          ≤0.06   100    0.0    ≤0.06   100    0.0    ≤0.06   98.6   0.0    0.12    100    0.0    ≤0.06   100    0.0    0.12    99.7   0.0
                        LVX        \-      \-     \-     8      86.2   13.8   0.25    95.5   4.5          0.5     95.7   2.2    4       89.0   9.6    4       89.9   8.7    0.5     92.7   7.3    0.12    100    0.0    0.5     92.6   6.6
                        AMK        \-      \-     \-     8      100    0.0    4       98.5   1.5          4       100    0.0    4       97.3   1.4    4       100    0.0    2       100    0.0    4       100    0.0    4       99.2   0.5
                        MIN        \-      \-     \-     16     86.2   10.3   8       88.1   7.5          16      84.8   10.9   8       84.9   6.9    8       76.8   2.9    8       78.0   9.8    8       84.6   5.1    8       83.7   6.8
  *K. pneumoniae*       TGC        2       92.2   0.0    1      100    0.0    2       92.7   1.1          1       99.2   0.0    1       94.8   1.5    2       96.5   2.0    2       95.6   0.4    2       97.5   0.0    2       95.8   0.9
                        AMP        ≥64     0.0    94.8   ≥64    1.2    82.6   ≥64     0.0    89.4         ≥64     0.8    93.7   ≥64     0.9    90.0   ≥64     1.0    91.0   ≥64     2.2    90.7   ≥64     5.6    89.4   ≥64     1.5    90.2
                        AMC        32      59.7   22.1   32     70.9   17.4   32      71.7   17.8         32      69.3   18.1   32      59.9   22.5   ≥64     53.0   35.5   ≥64     48.0   37.3   ≥64     56.3   28.1   ≥64     59.7   26.0
                        TZP        128     77.9   15.6   64     82.6   5.8    ≥256    80.6   16.8         ≥256    78.0   17.3   ≥256    70.5   21.6   ≥256    63.0   25.5   ≥256    57.8   33.8   ≥256    68.8   25.6   ≥256    70.4   22.2
                        CRO        ≥128    58.4   41.6   64     73.3   25.6   64      78.0   20.4         ≥128    66.1   32.3   ≥128    63.5   34.0   ≥128    60.0   37.5   ≥128    51.6   48.0   64      56.3   43.1   ≥128    62.8   35.7
                        FEP        16      84.4   9.1    16     89.5   7.0    16      86.9   9.4          ≥64     78.0   19.7   ≥64     77.2   20.4   ≥64     73.5   23.5   ≥64     59.6   38.7   ≥64     68.8   27.5   ≥64     75.4   21.6
                        IPM        1       98.6   0.0    0.5    98.8   0.0    0.5     91.5   0.9          \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     0.5     95.6   0.4
                        MEM        \-      \-     \-     \-     \-     \-     0.12    98.6   1.4          2       87.4   2.4    0.5     92.7   2.7    2       86.5   9.0    ≥32     80.4   16.4   ≥32     85.0   14.4   2       87.9   8.1
                        LVX        8       77.9   11.7   8      84.9   14.0   ≥16     85.9   12.6         ≥16     76.4   22.0   ≥16     76.3   21.6   ≥16     66.5   33.0   ≥16     56.4   42.2   ≥16     60.0   35.6   ≥16     71.8   25.9
                        AMK        16      92.2   0.0    8      94.2   5.8    4       93.2   6.3          16      91.3   8.7    64      89.1   10.3   32      88.5   8.0    32      85.8   6.7    32      88.8   1.9    32      89.7   6.9
                        MIN        16      68.8   23.4   16     83.7   11.6   ≥32     75.9   16.2         ≥32     78.7   16.5   ≥32     65.0   29.2   ≥32     57.0   23.5   ≥32     53.8   29.3   16      62.5   17.5   ≥32     65.9   22.7
  *P. aeruginosa*       TGC        ≥32     NA     NA     ≥32    NA     NA     ≥32     NA     NA           16      NA     NA     16      NA     NA     ≥32     NA     NA     16      NA     NA     16      NA     NA     16      NA     NA
                        AMP        ≥64     NA     NA     ≥64    NA     NA     ≥64     NA     NA           ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA
                        AMC        ≥64     NA     NA     ≥64    NA     NA     ≥64     NA     NA           ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA     ≥64     NA     NA
                        TZP        ≥256    54.2   30.6   128    69.9   12.6   128     67.2   16.7         ≥256    66.7   19.4   ≥256    62.2   24.1   ≥256    56.9   23.4   ≥256    55.0   32.9   128     67.8   17.8   ≥256    62.4   22.6
                        CAZ        ≥64     59.7   27.8   32     69.9   20.4   ≥64     62.9   24.7         ≥64     73.6   15.3   ≥64     61.1   28.1   ≥64     55.3   33.0   ≥64     55.4   32.9   32      69.8   21.8   ≥64     62.7   26.3
                        CRO        ≥128    NA     NA     ≥128   NA     NA     ≥128    NA     NA           ≥128    NA     NA     ≥128    NA     NA     ≥128    NA     NA     ≥128    NA     NA     64      NA     NA     ≥128    NA     NA
                        FEP        ≥64     44.4   29.2   32     65.0   16.5   ≥64     62.4   21.0         32      73.6   13.2   32      66.2   18.8   ≥64     66.0   21.8   32      60.8   19.8   32      63.9   20.8   32      64.1   19.7
                        IPM        16      58.6   32.9   8      68.0   17.5   16      62.2   27.0         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     16      63.4   25.1
                        MEM        \-      \-     \-     \-     \-     \-     ≥32     68.0   25.3         16      64.3   27.3   ≥32     65.6   27.0   ≥32     63.8   30.9   ≥32     57.2   32.9   ≥32     59.4   31.7   ≥32     62.6   29.6
                        LVX        ≥16     54.2   43.1   ≥16    51.5   40.8   ≥16     52.2   40.3         ≥16     52.8   38.9   ≥16     54.8   39.5   ≥16     55.9   37.2   ≥16     51.8   40.5   ≥16     61.4   35.1   ≥16     54.6   39.1
                        AMK        16      90.3   5.6    32     88.3   4.9    16      90.9   5.9          16      92.4   2.8    32      87.5   5.7    64      83.0   10.1   32      89.2   7.2    32      86.6   8.9    32      88.2   6.6
                        MIN        ≥32     NA     NA     ≥32    NA     NA     ≥32     NA     NA           ≥32     NA     NA     ≥32     NA     NA     ≥32     NA     NA     ≥32     NA     NA     ≥32     NA     NA     ≥32     NA     NA
  *S. marcescens*       TGC        2       92.9   0.0    2      100    0.0    2       94.4   0.0          2       100    0.0    2       97.1   0.0    2       97.3   0.0    2       94.7   2.1    2       94.8   2.1    2       96.3   0.6
                        AMP        ≥64     2.4    95.2   ≥64    7.1    81.0   ≥64     0.0    96.6         ≥64     0.0    82.8   ≥64     5.0    83.6   ≥64     8.0    69.3   ≥64     5.3    72.6   ≥64     1.0    75.3   ≥64     3.6    81.3
                        AMC        ≥64     2.4    92.9   ≥64    4.8    90.5   ≥64     5.6    94.4         ≥64     4.5    89.6   ≥64     3.6    92.1   ≥64     5.3    86.7   ≥64     5.3    92.6   ≥64     2.1    91.8   ≥64     4.2    91.5
                        TZP        16      90.5   7.1    8      95.2   0.0    64      77.8   10.0         4       98.5   0.0    16      90.7   2.9    16      92.0   5.3    4       95.8   1.1    8       94.8   3.1    16      91.5   3.7
                        CRO        32      64.3   23.8   16     83.3   14.3   32      74.4   23.3         1       94.0   4.5    16      77.9   16.4   32      80.0   20.0   8       81.1   13.7   2       82.5   7.2    16      79.9   15.1
                        FEP        8       92.9   7.1    4      100    0.0    2       94.4   4.4          ≤0.5    95.5   4.5    1       96.4   2.1    2       94.7   4.0    1       100    0.0    1       99.0   1.0    2       96.8   2.6
                        IPM        2       71.1   0.0    1      94.7   2.6    1       90.0   8.0          \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     2       85.7   4.0
                        MEM        \-      \-     \-     \-     \-     \-     0.12    100    0.0          0.12    100    0.0    0.5     99.3   0.7    0.12    98.7   1.3    0.25    93.7   4.2    0.25    99.0   1.0    0.25    98.3   1.3
                        LVX        1       92.9   4.8    1      97.6   0.0    2       90.0   1.1          2       91.0   1.5    2       91.4   5.7    4       89.3   2.7    2       91.6   6.3    2       96.9   3.1    2       92.3   3.6
                        AMK        8       100    0.0    8      97.6   2.4    8       98.9   0.0          4       97.0   0.0    4       96.4   0.7    16      96.0   2.7    4       98.9   1.1    8       95.9   1.0    8       97.4   0.9
                        MIN        8       64.3   4.8    4      97.6   2.4    8       84.4   1.1          8       86.6   3.0    16      66.4   11.4   16      54.7   13.3   16      57.9   13.7   16      66.0   12.4   8       70.2   8.8

^a^ AMK = amikacin; AMC = amoxicillin-clavulanate; AMP = ampicillin; FEP = cefepime; CAZ = ceftazidime; CRO = ceftriaxone; IPM = imipenem; LVX = levofloxacin; MEM = meropenem; MIN = minocycline; TZP = piperacillin-tazobactam; TGC = tigecycline. NA = susceptibility or resistance breakpoint not available. - MIC90, %S and %R are not given where N ≤20. No imipenem data was collected after 2006. Susceptible (S), resistance (R) breakpoints (mg/L): *A. baumannii*: TZP, S ≤ 16, R ≥ 128; CAZ, S ≤ 8, R ≥ 32; CRO, S ≤ 8, R ≥ 64; FEP, S ≤ 8, R ≥ 32; IPM, S≤= 4, R ≥ 16; MEM, S ≤ 4, R ≥ 16; LVX, S≤= 2, R ≥ 8; AMK, S ≤ 16, R ≥ 64; MIN, S ≤ 4, R ≥ 16; *Enterobacter* spp.: TGC, S ≤ 2, R ≥ 8; AMP, S ≤ 8, R ≥ 32; AMC, S ≤ 8, R ≥ 32; TZP, S ≤ 16, R ≥ 128; CRO, S ≤ 1, R ≥ 4; FEP, S ≤ 8, R ≥ 32; IPM, S ≤ 1, R ≥ 4; MEM, S ≤ 1, R ≥ 4; LVX, S ≤ 2, R ≥ 8; AMK, S ≤ 16, R ≥ 64; MIN, S ≤ 4, R ≥ 16; *E. coli*: TGC, S ≤ 2, R ≥ 8; AMP, S ≤ 8, R ≥ 32; AMC, S ≤ 8, R ≥ 32; TZP, S ≤ 16, R ≥ 128; CRO, S ≤ 1, R ≥ 4; FEP, S ≤ 8, R ≥ 32; IPM, S ≤ 1, R ≥ 4; MEM, S ≤ 1, R ≥ 4; LVX, S ≤ 2, R ≥ 8; AMK, S ≤ 16, R ≥ 64; MIN, S ≤ 4, R ≥ 16; *H. influenza*: TIG, S ≤ 0.25; AMP, S ≤ 1, R ≥ 4; AMC, S ≤ 4, R ≥ 8; CRO, S ≤ 2; FEP, S ≤ 2; IPM, S ≤ 4; MEM, S ≤ 0.5; LVX, S ≤ 2; MIN, S ≤ 2, R ≥ 8; *Klebsiella* spp.: TIG, S ≤ 2, R ≥ 8; AMP, S ≤ 8, R ≥ 32; AMC, S ≤ 8, R ≥ 32; TZP, S ≤ 16, R ≥ 128; CRO, S ≤ 1, R ≥ 4; FEP, S ≤ 8, R ≥ 32; IPM, S ≤ 1, R ≥ 4; MEM, S ≤ 1, R ≥ 4; LVX, S ≤ 2, R ≥ 8; AMK, S ≤ 16, R ≥ 64; MIN, S ≤ 4, R ≥ 16; *P. aeruginosa*: TZP, S ≤ 16, R ≥ 128; CAZ, S ≤ 8, R ≥ 32; FEP, S ≤ 8, R ≥ 32; IPM, S ≤ 2, R ≥ 8; MEM, S ≤ 2, R ≥ 8; LVX, S ≤ 2, R ≥ 8; AMK, S ≤ 16, R ≥ 64; *S. marcescens*: TGC, S ≤ 2, R ≥ 8; AMP, S ≤ 8, R ≥ 32; AMC, S ≤ 8, R ≥ 32; TZP, S ≤ 16, R ≥ 128; CRO, S ≤ 1, R ≥ 4; FEP, S ≤ 8, R ≥ 32; IPM, S ≤ 1, R ≥ 4; MEM, S ≤ 1, R ≥ 4; LVX, S ≤ 2, R ≥ 8; AMK, S ≤ 16, R ≥ 64; MIN, S ≤ 4, R ≥ 16.
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###### 

MIC~90~ (mg/L), antimicrobial susceptibility (%S), and antimicrobial resistance (%R) for Gram-positive isolates collected in Italy during T.E.S.T. 2004--2011.

  Organism            Agent^a^   2004    2005   2006   2007    2008   2009   2010    2011   2004--2011                                                                                                                                 
  ------------------- ---------- ------- ------ ------ ------- ------ ------ ------- ------ ------------ ------- ------ ------ ------- ------- ------ ------- ------ ------ ------- ------ ------ ------- ------ ------ ------- ------ ------
  *E. faecalis*       TGC        0.25    96.9   NA     0.25    100    NA     0.25    100    NA           0.25    100    NA     0.25    100     NA     0.25    100    NA     0.25    99.1   NA     0.12    100    NA     0.25    99.7   NA
                      AMP        2       100    0.0    1       100    0.0    2       100    0.0          2       100    0.0    2       100     0.0    2       100    0.0    2       97.4   2.6    1       100    0.0    2       99.6   0.4
                      PEN        8       100    0.0    4       100    0.0    4       100    0.0          4       100    0.0    8       100.0   0.0    8       100    0.0    8       97.4   2.6    4       100    0.0    8       99.6   0.4
                      AMC        2       NA     NA     1       NA     NA     1       NA     NA           1       NA     NA     2       NA      NA     2       NA     NA     1       NA     NA     1       NA     NA     1       NA     NA
                      TZP        8       NA     NA     8       NA     NA     8       NA     NA           8       NA     NA     8       NA      NA     16      NA     NA     8       NA     NA     4       NA     NA     8       NA     NA
                      CRO        ≥128    NA     NA     ≥128    NA     NA     ≥128    NA     NA           ≥128    NA     NA     ≥128    NA      NA     ≥128    NA     NA     ≥128    NA     NA     ≥128    NA     NA     ≥128    NA     NA
                      IPM        4       NA     NA     2       NA     NA     8       NA     NA           \-      \-     \-     \-      \-      \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     8       NA     NA
                      MEM        \-      \-     \-     8       NA     NA     16      NA     NA           16      NA     NA     8       NA      NA     16      NA     NA     8       NA     NA     8       NA     NA     8       NA     NA
                      LVX        32      56.3   43.8   32      71.2   25.0   ≥64     62.3   37.7         32      70.2   29.8   ≥64     69.7    29.5   ≥64     66.3   28.3   ≥64     60.0   39.1   ≥64     63.8   34.6   ≥64     65.3   33.2
                      LZD        2       100    0.0    2       100    0.0    2       100    0.0          2       100    0.0    2       100.0   0.0    2       100    0.0    2       100    0.0    2       100    0.0    2       100    0.0
                      MIN        ≥16     37.5   25.0   ≥16     36.5   13.5   ≥16     28.3   28.3         ≥16     29.8   42.9   ≥16     21.2    47.7   ≥16     14.1   58.7   ≥16     16.5   61.7   ≥16     32.3   12.6   ≥16     25.3   38.5
                      VAN        ≥64     81.3   18.8   2       96.2   3.9    2       97.2   2.8          2       97.6   2.4    2       95.5    3.8    2       96.7   3.3    4       95.7   4.4    2       100    0.0    2       96.4   3.5
  *E. faecium*        TGC        0.12    100    NA     \-      \-     \-     0.12    100    NA           \-      \-     \-     0.25    96.1    NA     0.25    100    NA     0.25    100    NA     0.06    100    NA     0.25    98.8   NA
                      AMP        ≥32     40.9   59.1   \-      \-     \-     ≥32     10.0   90.0         \-      \-     \-     ≥32     15.5    84.5   ≥32     26.0   74.0   ≥32     24.4   75.6   ≥32     22.0   78.0   ≥32     20.2   79.8
                      PEN        ≥16     36.4   63.6   \-      \-     \-     ≥16     7.5    92.5         \-      \-     \-     ≥16     31.1    68.9   ≥16     22.0   78.0   ≥16     35.6   64.4   ≥16     53.7   46.3   ≥16     29.5   70.5
                      AMC        ≥16     NA     NA     \-      \-     \-     ≥16     NA     NA           \-      \-     \-     ≥16     NA      NA     ≥16     NA     NA     ≥16     NA     NA     ≥16     NA     NA     ≥16     NA     NA
                      TZP        ≥32     NA     NA     \-      \-     \-     ≥32     NA     NA           \-      \-     \-     ≥32     NA      NA     ≥32     NA     NA     ≥32     NA     NA     ≥32     NA     NA     ≥32     NA     NA
                      CRO        ≥128    NA     NA     \-      \-     \-     ≥128    NA     NA           \-      \-     \-     ≥128    NA      NA     ≥128    NA     NA     ≥128    NA     NA     ≥128    NA     NA     ≥128    NA     NA
                      IPM        ≥32     NA     NA     \-      \-     \-     ≥32     NA     NA           \-      \-     \-     \-      \-      \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥32     NA     NA
                      MEM        \-      \-     \-     \-      \-     \-     ≥32     NA     NA           \-      \-     \-     ≥32     NA      NA     ≥32     NA     NA     ≥32     NA     NA     ≥32     NA     NA     ≥32     NA     NA
                      LVX        ≥64     27.3   72.7   \-      \-     \-     ≥64     15.0   85.0         \-      \-     \-     ≥64     6.8     89.3   ≥64     14.0   82.0   ≥64     13.3   77.8   ≥64     12.2   85.4   ≥64     12.5   83.0
                      LZD        2       100    0.0    \-      \-     \-     2       100    0.0          \-      \-     \-     2       98.1    1.9    2       100    0.0    2       97.8   0.0    2       100    0.0    2       99.1   0.6
                      MIN        ≥16     68.2   18.2   \-      \-     \-     8       80.0   5.0          \-      \-     \-     ≥16     84.5    11.7   ≥16     70.0   28.0   ≥16     71.1   15.6   4       90.2   2.4    ≥16     78.9   13.1
                      VAN        ≥64     77.3   18.2   \-      \-     \-     ≥64     50.0   47.5         \-      \-     \-     ≥64     85.4    13.6   ≥64     88.0   12.0   ≥64     84.4   13.3   1       100    0.0    ≥64     82.1   16.4
  *S. aureus*         TGC        0.25    100    NA     0.25    100    NA     0.25    100    NA           0.25    100    NA     0.25    100     NA     0.5     100    NA     0.25    100    NA     0.25    100    NA     0.25    100    NA
                      AMP        ≥32     17.6   82.4   ≥32     23.9   76.1   ≥32     18.4   81.6         ≥32     15.0   85.0   ≥32     16.2    83.8   ≥32     17.0   83.0   ≥32     18.3   81.7   ≥32     18.8   81.2   ≥32     17.7   82.3
                      PEN        ≥16     17.6   82.4   ≥16     20.4   79.6   ≥16     18.0   82.0         ≥16     13.9   86.1   ≥16     13.3    86.7   ≥16     16.5   83.5   ≥16     16.2   83.8   ≥16     15.4   84.6   ≥16     15.8   84.2
                      AMC        ≥16     59.3   40.7   ≥16     66.4   33.6   ≥16     73.7   26.3         ≥16     79.7   20.3   ≥16     74.2    25.8   ≥16     75.4   24.6   ≥16     64.7   35.3   ≥16     68.4   31.6   ≥16     71.3   28.7
                      TZP        ≥32     62.6   37.4   ≥32     68.1   31.9   ≥32     76.0   24.0         ≥32     80.7   19.3   ≥32     76.9    23.1   ≥32     78.1   21.9   ≥32     77.7   22.3   ≥32     73.5   26.5   ≥32     75.7   24.3
                      CRO        ≥128    56.0   39.6   ≥128    64.6   32.7   ≥128    69.1   22.1         ≥128    76.5   18.7   ≥128    66.8    21.3   ≥128    69.6   21.0   ≥128    65.5   20.9   ≥128    67.9   25.6   ≥128    67.7   23.3
                      IPM        ≥32     69.9   30.1   ≥32     68.0   32.0   ≥32     84.3   15.7         \-      \-     \-     \-      \-      \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥32     73.9   26.1
                      MEM        \-      \-     \-     ≥32     76.9   23.1   ≥32     76.6   21.9         ≥32     83.4   15.0   ≥32     83.8    14.1   ≥32     83.0   12.9   16      83.1   11.2   ≥32     75.2   20.5   ≥32     81.3   15.4
                      LVX        8       56.0   40.7   32      61.1   37.2   16      64.5   33.2         16      71.1   28.9   16      64.6    34.3   32      62.9   36.6   32      60.4   38.1   32      62.4   35.9   32      63.4   35.2
                      LZD        4       100    0.0    4       100    0.0    4       100    0.0          4       100    0.0    4       100     0.0    4       100    0.0    2       100    0.0    2       100    0.0    4       100    0.0
                      MIN        2       100    0.0    0.5     99.1   0.0    ≤0.25   98.6   0.5          0.5     97.9   0.5    0.5     98.1    0.3    1       95.1   4.0    0.5     97.1   0.7    0.5     99.1   0.4    0.5     97.9   0.9
                      VAN        2       100    0.0    1       100    0.0    1       100    0.0          1       100    0.0    1       100     0.0    1       100    0.0    1       100    0.0    1       100    0.0    1       100    0.0
  *S. agalactiae*     TGC        0.12    100    NA     0.12    100    NA     0.12    100    NA           0.12    100    NA     0.12    100     NA     0.06    100    NA     0.25    100    NA     0.25    100    NA     0.12    100    NA
                      AMP        0.12    100    NA     0.12    100    NA     0.12    100    NA           0.12    100    NA     0.12    100     NA     0.12    100    NA     0.12    100    NA     0.12    100    NA     0.12    100    NA
                      PEN        ≤0.06   100    NA     0.12    100    NA     0.12    100    NA           0.12    100    NA     0.12    100     NA     0.12    100    NA     ≤0.06   100    NA     0.12    100    NA     0.12    100    NA
                      AMC        0.06    NA     NA     0.12    NA     NA     0.12    NA     NA           0.12    NA     NA     0.06    NA      NA     0.12    NA     NA     0.12    NA     NA     0.12    NA     NA     0.12    NA     NA
                      TZP        ≤0.25   NA     NA     ≤0.25   NA     NA     ≤0.25   NA     NA           0.5     NA     NA     ≤0.25   NA      NA     0.5     NA     NA     0.5     NA     NA     0.5     NA     NA     0.5     NA     NA
                      CRO        0.06    100    NA     0.12    100    NA     0.12    100    NA           0.12    100    NA     0.06    100     NA     0.12    100    NA     0.12    100    NA     0.12    100    NA     0.12    100    NA
                      IPM        0.25    NA     NA     ≤0.12   NA     NA     ≤0.12   NA     NA           \-      \-     \-     \-      \-      \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     0.25    NA     NA
                      MEM        \-      \-     \-     ≤0.12   100    NA     ≤0.12   100    NA           ≤0.12   100    NA     ≤0.12   100     NA     ≤0.12   100    NA     ≤0.12   100    NA     ≤0.12   100    NA     ≤0.12   100    NA
                      LVX        1       100    0.0    1       100    0.0    1       98.9   0.0          1       97.2   1.4    1       99.2    0.8    1       97.4   2.6    1       100    0.0    1       98.3   1.7    1       98.9   0.8
                      LZD        1       100    NA     1       100    NA     1       100    NA           1       100    NA     1       100     NA     1       100    NA     2       100    NA     2       100    NA     1       100    NA
                      MIN        ≥16     38.9   58.3   ≥16     5.0    82.5   ≥16     24.2   67.0         ≥16     12.5   83.3   ≥16     19.5    72.2   ≥16     15.8   75.0   ≥16     20.8   75.5   ≥16     15.5   81.0   ≥16     19.0   74.3
                      VAN        0.5     100    NA     0.5     100    NA     0.5     100    NA           0.5     100    NA     0.5     100     NA     0.5     100    NA     1       100    NA     0.5     100    NA     0.5     100    NA
  *S. pneumoniae\**   TGC        0.06    100    \-     0.06    100    \-     0.06    100    \-           0.06    100    \-     0.06    100     \-     0.03    100    \-     0.03    100    \-     0.03    100    \-     0.06    100    \-
                      AMP        ≤0.06   \-     \-     0.5     \-     \-     0.12    \-     \-           0.12    \-     \-     1       \-      \-     2       \-     \-     4       \-     \-     2       \-     \-     0.5     \-     \-
                      PEN        0.25    73.2   4.9    0.5     80.0   4.6    0.25    73.0   4.5          0.25    75.0   5.6    1       73.4    7.7    1       74.3   9.5    2       67.4   14.1   1       72.4   3.4    0.5     73.4   7.5
                      AMC        0.06    100    0.0    0.5     98.5   0.0    0.12    99.1   0.0          0.06    97.6   2.4    0.5     96.5    2.1    1       96.2   1.9    2       91.3   3.3    1       96.6   0.0    0.5     96.7   1.5
                      TZP        ≤0.25   \-     \-     0.5     \-     \-     ≤0.25   \-     \-           ≤0.25   \-     \-     1       \-      \-     4       \-     \-     4       \-     \-     4       \-     \-     1       \-     \-
                      CRO        0.12    97.6   2.4    0.25    100    0.0    0.12    98.2   0.0          0.5     100    0.0    0.5     94.4    2.8    1       93.3   1.0    1       92.4   0.0    0.5     100    0.0    0.5     96.3   0.9
                      AZM        ≥128    63.4   36.6   ≥128    44.2   55.8   ≥128    59.8   40.2         64      72.7   27.3   ≥128    64.0    36.0   ≥128    48.5   51.5   64      47.3   52.7   64      50.0   50.0   ≥128    56.6   43.4
                      CLR        ≥128    63.4   36.6   ≥128    44.2   55.8   ≥128    59.8   39.2         64      74.5   25.5   ≥128    64.0    35.2   ≥128    48.5   51.5   64      48.4   51.6   64      50.0   50.0   ≥128    57.0   42.7
                      ERY        ≥128    63.4   36.6   ≥128    44.2   55.8   ≥128    58.8   39.2         64      70.9   29.1   ≥128    63.2    36.8   ≥128    48.5   51.5   64      47.3   52.7   64      50.0   50.0   ≥128    56.1   43.5
                      CLI        ≥128    68.3   31.7   ≥128    65.1   34.9   ≥128    76.3   23.7         ≥128    80.0   20.0   ≥128    67.2    32.8   ≥128    60.4   38.6   ≥128    59.3   40.7   ≥128    57.1   42.9   ≥128    67.0   32.9
                      IPM        ≤0.12   93.3   0.0    ≤0.12   91.7   4.2    ≤0.12   98.3   1.7          \-      \-     \-     \-      \-      \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≤0.12   95.1   2.5
                      MEM        0.5     88.5   3.8    1       82.4   11.8   0.25    92.3   5.8          ≤0.12   92.9   4.8    0.25    90.2    4.9    0.5     89.5   5.7    0.5     87.0   6.5    0.5     89.7   3.4    0.5     89.8   5.5
                      LVX        1       100    0.0    2       98.5   1.5    1       96.4   1.8          1       100    0.0    2       99.3    0.0    2       97.1   1.9    1       100    0.0    1       100    0.0    1       98.7   0.7
                      LZD        1       100    \-     1       100    \-     1       100    \-           1       100    \-     1       100     \-     1       100    \-     1       100    \-     1       100    \-     1       100    \-
                      MIN        8       75.6   22.0   8       72.3   23.1   8       70.3   20.7         8       71.4   20.2   ≥16     38.5    47.6   ≥16     26.7   58.1   ≥16     28.3   57.6   ≥16     55.2   31.0   ≥16     50.9   38.1
                      VAN        0.5     100    \-     0.5     100    \-     0.5     100    \-           0.5     100    \-     0.5     100     \-     0.5     100    \-     0.5     100    \-     0.5     100    \-     0.5     100    \-

^a^ AMC = amoxicillin-clavulanate; AMP = ampicillin; AZM = azithromycin; CRO = ceftriaxone; CLR = clarithromycin; CLI = clindamycin; ERY = erythromycin; IPM = imipenem; LVX = levofloxacin; LZD = linezolid; MEM = meropenem; MIN = minocycline; PEN = penicillin; TZP = piperacillin-tazobactam; TGC = tigecycline; VAN = vancomycin. NA = susceptibility or resistance breakpoint not available. - MIC90, %S and %R are not given where N ≤20. No imipenem data was collected after 2006. \* Tetracycline breakpoints for *S. pneumoniae* are used here for minocycline. Susceptible (S), resistance (R) breakpoints: *Enterococcus* spp.: TGC, S ≤ 0.25; AMP, S ≤ 8, R ≥ 16; PEN, S ≤ 8, R ≥ 16; LVX, S ≤ 2, R ≥ 8; LZD, S ≤ 2, R ≥ 8; MIN, S ≤ 4, R ≥ 16; VAN, S ≤ 4, R ≥ 32; *S. aureus*: TGC, S ≤ 0.5; AMP, S ≤ 0.25, R ≥ 0.5; PEN, S ≤ 0.12, R ≥ 0.25; AMC, S ≤ 4, R ≥ 8; TZP, S ≤ 8, R ≥ 16; CRO, S ≤ 8, R ≥ 64; IPM, S ≤ 4, R ≥ 16; MEM, S ≤ 4, R ≥ 16; LVX, S ≤ 1, R ≥ 4; LZD, S ≤ 4, R ≥ 8; MIN, S ≤ 4, R ≥ 16; VAN, S ≤ 2, R ≥ 16; *S. agalactiae*: TGC, S ≤ 0.25; AMP, S ≤ 0.25; PEN, S ≤ 0.12; CRO, S ≤ 0.5; MEM, S ≤ 0.5; LVX, S ≤ 2, R ≥ 8; LZD, S ≤ 2; MIN, S ≤ 2, R ≥ 8; VAN, S ≤ 1; *S. pneumoniae*: TGC, S ≤ 0.06; PEN, S ≤ 0.06, R ≥ 2; AMC, S ≤ 2, R ≥ 8; CRO, S ≤ 1, R ≥ 4; AZM, S ≤ 0.5, R ≥ 2; CLR, S ≤ 0.25, R ≥ 1; ERY, S ≤ 0.25, R ≥ 1; CLI, S ≤ 0.25, R ≥ 1; IPM, S ≤ 0.12, R ≥ 1; MEM, S ≤ 0.25, R ≥ 1; LVX, S ≤ 2, R ≥ 8; LZD, S ≤ 2; MIN, S ≤ 2, R ≥ 8; VAN, S ≤ 1.

pharmaceuticals-06-01381-t004_Table 4

###### 

Overall prevalence (N), susceptibility (%S) and resistance (%R) among multidrug-resistant isolates of *A. baumannii* and *P. aeruginosa* collected in Italy during T.E.S.T. 2004--2011.

  Organism            Agent^a^            2004                 2005         2006         2007         2008         2009         2010                   2011       2004--2011                                                                             
  ------------------- ------------------- -------------------- ------------ ------------ ------------ ------------ ------------ ---------------------- ---------- ---------------- -------- -------- -------- -------- -------- -------- -------- ------ ------
  *A. baumannii*      TZP                 7.7                  92.3         0.0          80.0         3.4          78.0         4.8                    90.5       0.9              94.0     1.2      96.4     0.0      99.0     1.0      98.0     1.5    93.7
                      CAZ                 0.0                  92.3         0.0          90.0         0.0          98.3         0.0                    100        1.7              95.7     0.0      97.6     1.9      95.2     5.1      91.8     1.7    95.6
                      CRO                 0.0                  100          0.0          90.0         0.0          98.3         0.0                    100        0.0              100      0.0      100      1.0      98.1     3.1      89.8     0.8    97.3
                      FEP                 0.0                  84.6         10.0         50.0         1.7          81.4         0.0                    90.5       2.6              84.6     10.8     71.1     6.7      77.9     2.0      78.6     4.4    79.5
                      IPM                 46.2                 53.8         \-           \-           50.0         32.1         \-                     \-         \-               \-       \-       \-       \-       \-       \-       \-       49.0   38.8
                      MEM                 \-                   \-           \-           \-           6.5          83.9         38.1                   52.4       21.4             59.8     4.8      81.9     1.0      95.2     1.0      98.0     10.3   80.3
                      LVX                 0.0                  100          0.0          100          0.0          93.2         0.0                    95.2       0.0              98.3     0.0      97.6     0.0      100      0.0      100      0.0    98.1
                      AMK                 23.1                 76.9         20.0         80.0         8.5          88.1         0.0                    100        14.5             82.1     2.4      96.4     18.3     80.8     4.1      89.8     9.9    87.5
                      MIN                 100                  0.0          100          0.0          94.9         1.7          100                    0.0        82.1             3.4      57.8     10.8     37.5     10.6     62.2     2.0      69.4   5.1
  **Organism**        **Agent^a^**        **2004**             **2005**     **2006**     **2007**     **2008**     **2009**     **2010**               **2011**   **2004--2011**                                                                         
  **N = 19 (17/2)**   **N = 13 (12/1)**   **N = 33 (19/14)**   **N = 20**   **N = 65**   **N = 43**   **N = 49**   **N = 38**   **N = 280 (48/232)**                                                                                                     
  **%S**              **%R**              **%S**               **%R**       **%S**       **%R**       **%S**       **%R**       **%S**                 **%R**     **%S**           **%R**   **%S**   **%R**   **%S**   **%R**   **%S**   **%R**          
  *P. aeruginosa*     TZP                 21.1                 52.6         23.1         38.5         27.3         51.5         15.0                   75.0       10.8             72.3     7.0      62.8     4.1      87.8     7.9      52.6     12.1   65.7
                      CAZ                 21.1                 63.2         15.4         84.6         6.1          75.8         25.0                   75.0       6.2              83.1     9.3      86.0     4.1      77.6     2.6      76.3     8.6    78.9
                      FEP                 0.0                  73.7         15.4         53.8         3.0          81.8         25.0                   55.0       9.2              70.8     14.0     67.4     8.2      51.0     0.0      86.8     8.6    68.6
                      IPM                 0.0                  100          0.0          100          0.0          100          \-                     \-         \-               \-       \-       \-       \-       \-       \-       \-       0.0    100
                      MEM                 \-                   \-           \-           \-           0.0          100          0.0                    100        1.5              96.9     2.3      95.3     0.0      95.9     0.0      97.4     0.9    97.0
                      LVX                 5.3                  94.7         0.0          100          0.0          100          0.0                    90.0       0.0              100      2.3      97.7     0.0      100      0.0      100      0.7    98.6
                      AMK                 78.9                 10.5         38.5         38.5         66.7         21.2         65.0                   20.0       53.8             21.5     55.8     32.6     65.3     26.5     39.5     44.7     57.5   27.1

^a^ AMK = amikacin; FEP = cefepime; CAZ = ceftazidime; CRO = ceftriaxone; IPM = imipenem; LVX = levofloxacin; MEM = meropenem; MIN = minocycline; TZP = piperacillin-tazobactam.. N = total number of isolates; numbers in parentheses represent total isolate number tested against imipenem and meropenem, respectively; where no parentheses are given, all isolates were tested against imipenem (2004--2006) or meropenem (2007--2011). - %S and %R are not given where N \<10. No imipenem data was collected after 2006.

### 3.1.3. *E.* *coli*

Amikacin, meropenem and tigecycline were all effective against *E. coli*, with \>95% susceptibility during all years of surveillance ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}). Susceptibility of *E. coli* to cefepime was 93.4% in 2004, but this decreased to 77.4% in 2011, with some fluctuation in susceptibility during the years in between. *E. coli* were 28.4% susceptible to ampicillin and approximately 50% susceptible to levofloxacin from 2004--2011. The proportion of ESBL-producing *E. coli* in Italy was initially low from 2004 to 2007 (ranging from 12.6% in 2006 to 19.8% in 2004), but were notably higher between 2008 and 2011 (28.0--35.8%; [Table 5](#pharmaceuticals-06-01381-t005){ref-type="table"}). Tigecycline, meropenem and amikacin were highly active against ESBL-positive *E. coli* (100%, 98.8% and 94.2% susceptible, respectively) in this study ([Table 6](#pharmaceuticals-06-01381-t006){ref-type="table"}). *E. coli* were 99.5% susceptible to imipenem ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}) while 96.8% of ESBL-producing isolates were imipenem-susceptible ([Table 6](#pharmaceuticals-06-01381-t006){ref-type="table"}).

### 3.1.4. *H.* *influenzae*

Isolates of *H. influenzae* were highly susceptible (\>97.8% except for ampicillin \[\>87%\] from 2004--2011) to all T.E.S.T. agents for which breakpoints were available ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}). Amikacin exhibited low activity against this pathogen (overall MIC~90~ 8 mg/L). The resistance of *H. influenzae* to ampicillin fluctuated during T.E.S.T., ranging from 2.6% in 2009 to 15.0% in 2010. The frequency of β-lactamase-producing *H. influenzae* peaked in Italy in 2005 (15.5%), and was lowest in 2009 (3.5%; [Table 5](#pharmaceuticals-06-01381-t005){ref-type="table"}), but there were no notable trends. All *H. influenzae* were imipenem-susceptible between 2004 and 2006 ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}).

### 3.1.5. *K.* *oxytoca*

*K. oxytoca* were susceptible to most antimicrobials on the T.E.S.T. panel ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}). For all years combined, susceptibility was between 90%-100% for amikacin, cefepime, levofloxacin, meropenem and tigecycline; 80%-90% for ceftriaxone, minocycline and piperacillin-tazobactam; and was 77.1% for amoxicillin-clavulanate. The proportion of ESBL-producing *K. oxytoca* was highest in 2004 (12.5%) and 2008 (12.3%), but was low (\<5%) in all other years, giving an overall value of 5.0% ([Table 5](#pharmaceuticals-06-01381-t005){ref-type="table"}). Tigecycline, amoxicillin-clavulanate, meropenem and amikacin maintained good activity (≥94.7% susceptibility) against ESBL-positive isolates of *K. oxytoca* ([Table 6](#pharmaceuticals-06-01381-t006){ref-type="table"}). In total, 98.8% of *K. oxytoca* isolates were susceptible to imipenem (2004--2006) ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}).

### 3.1.6. *K.* *pneumoniae*

*K. pneumoniae* were less susceptible than *K. oxytoca* to most agents, apart from tigecycline for which 95.8% susceptibility was noted over all years ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}). From 2004 to 2011, *K. pneumoniae* were 80--90% susceptible to amikacin and meropenem, and 70--80% susceptible to cefepime, levofloxacin and piperacillin-tazobactam in Italy. The numbers of ESBL-producing *K. pneumoniae* ranged from 16.8% (2006) to 35.1% (2004), giving an overall value of 24.1% from 2004--2011 ([Table 5](#pharmaceuticals-06-01381-t005){ref-type="table"}). The most active agents against ESBL-positive *K. pneumoniae* were tigecycline (92.9% susceptible) and meropenem (81.2%) ([Table 6](#pharmaceuticals-06-01381-t006){ref-type="table"}). Among all *K. pneumoniae*, 95.6% of isolates were imipenem-susceptible between 2004 and 2006 ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}) while 86.2% of ESBL-positive isolates were susceptible ([Table 6](#pharmaceuticals-06-01381-t006){ref-type="table"}).

pharmaceuticals-06-01381-t005_Table 5

###### 

Overall prevalence (N) and rate of resistant isolates (n, %) among Gram-negative and Gram-positive isolates collected in Italy during T.E.S.T. 2004--2011.

  Organism                                2004    2005   2006     2007   2008     2009   2010     2011   2004--2011                                                                      
  --------------------------------------- ------- ------ -------- ------ -------- ------ -------- ------ ------------ ------ -------- ------ --------- ------ -------- ------ ---------- ------
  **Gram-negative**                                                                                                                                                                      
  ESBL-producing *E. coli*                18/91   19.8   18/139   12.9   32/254   12.6   28/190   14.7   121/432      28.0   76/252   30.2   102/285   35.8   84/288   29.2   479/1931   24.8
  β-lactamase-producing *H. influenzae*   5/45    11.1   11/71    15.5   12/109   11.0   11/75    14.7   23/155       14.8   4/115    3.5    12/80     15.0   6/89     6.7    84/739     11.4
  ESBL-producing *K. oxytoca*             2/16    12.5   0/29     0.0    2/67     3.0    1/46     2.2    9/73         12.3   3/69     4.3    2/41      4.9    0/39     0.0    19/380     5.0
  ESBL-producing *K. pneumoniae*          27/77   35.1   18/86    20.9   32/191   16.8   33/127   26.0   82/329       24.9   42/200   21.0   73/225    32.4   29/160   18.1   336/1395   24.1
  **Gram-positive**                                                                                                                                                                      
  Vancomycin-resistant *E. faecalis*      6/32    18.8   2/52     3.8    3/106    2.8    2/84     2.4    5/132        3.8    3/92     3.3    5/115     4.3    0/127    0.0    26/740     3.5
  Vancomycin-resistant *E. faecium*       4/22    18.2   4/16     25.0   19/40    47.5   2/19     10.5   14/103       13.6   6/50     12.0   6/45      13.3   0/41     0.0    55/336     16.4
  Methicillin-resistant *S. aureus*       41/91   45.1   43/113   38.1   72/217   33.2   52/187   27.8   128/376      34.0   66/224   29.5   103/278   37.1   77/234   32.9   582/1720   33.8
  Penicillin-resistant *S. pneumoniae*    2/41    4.9    3/65     4.6    5/111    4.5    5/84     6.0    11/143       7.7    10/105   9.5    13/92     14.1   1/29     3.4    50/670     7.5

n = number of resistant isolates; N = total number of isolates. ESBL = extended-spectrum β-lactamase.

pharmaceuticals-06-01381-t006_Table 6

###### 

MIC~90~ (mg/L), antimicrobial susceptibility (%S), and antimicrobial resistance (%R) for resistant Gram-negative and Gram-positive isolates collected in Italy during T.E.S.T. 2004--2011.

  Organism                       Agent^a^   2004   2005   2006   2007    2008   2009   2010    2011   2004--11                                                                                                                                
  ------------------------------ ---------- ------ ------ ------ ------- ------ ------ ------- ------ ---------- ------- ------ ------ ------- ------ ------ ------- ------ ------ ------- ------ ------ ------- ------ ------ ------- ------ ------
  ESBL-positive*E. coli*         TGC        0.25   100    0.0    0.5     100    0.0    0.5     100    0.0        0.5     100    0.0    0.5     100    0.0    0.5     100    0.0    0.5     100    0.0    0.5     100    0.0    0.5     100    0.0
                                 AMP        ≥64    0.0    100    ≥64     0.0    100    ≥64     0.0    100        ≥64     0.0    100    ≥64     0.0    100    ≥64     0.0    100    ≥64     0.0    100    ≥64     0.0    100    ≥64     0.0    100
                                 AMC        ≥64    16.7   55.6   ≥64     11.1   50.0   32      18.8   34.4       32      17.9   21.4   32      25.6   28.9   32      13.2   39.5   32      19.6   30.4   32      50.0   13.1   32      24.8   29.9
                                 TZP        ≥256   61.1   27.8   ≥256    66.7   22.2   64      71.9   6.3        64      67.9   7.1    128     66.9   15.7   ≥256    53.9   17.1   128     68.6   11.8   64      79.8   8.3    128     67.6   13.4
                                 CRO        ≥128   16.7   77.8   ≥128    0.0    94.4   ≥128    0.0    100        ≥128    0.0    100    ≥128    0.0    100    ≥128    0.0    100    ≥128    3.9    96.1   64      0.0    97.6   ≥128    1.5    97.7
                                 FEP        ≥64    66.7   22.2   ≥64     16.7   72.2   ≥64     18.8   59.4       ≥64     14.3   75.0   ≥64     26.4   59.5   ≥64     23.7   72.4   ≥64     26.5   54.9   ≥64     34.5   47.6   ≥64     27.3   58.5
                                 IPM        0.5    100    0.0    0.5     100    0.0    0.5     92.6   0.0        \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     0.5     96.8   0.0
                                 MEM        \-     \-     \-     \-      \-     \-     \-      \-     \-         0.12    100    0.0    0.12    96.7   0.8    ≤0.06   98.7   0.0    ≤0.06   100    0.0    ≤0.06   100    0.0    ≤0.06   98.8   0.2
                                 LVX        ≥16    27.8   72.2   ≥16     16.7   83.3   ≥16     6.3    90.6       ≥16     10.7   85.7   ≥16     9.9    87.6   ≥16     11.8   88.2   ≥16     10.8   89.2   ≥16     10.7   82.1   ≥16     11.3   86.4
                                 AMK        16     100    0.0    32      88.9   5.6    16      93.8   3.1        16      92.9   3.6    16      90.1   5.0    16      93.4   2.6    16      96.1   1.0    16      98.8   0.0    16      94.2   2.5
                                 MIN        ≥32    61.1   33.3   ≥32     61.1   16.7   ≥32     65.6   28.1       16      71.4   17.9   16      67.8   14.0   16      69.7   14.5   16      57.8   22.5   16      75.0   13.1   16      66.8   17.7
  BL-pos *H. influenzae*         TGC        \-     \-     \-     0.25    100    NA     0.25    100    NA         0.25    100    NA     0.25    100    NA     \-      \-     \-     0.25    100    NA     \-      \-     \-     0.25    100    NA
                                 AMP        \-     \-     \-     ≥64     9.1    90.9   32      0.0    83.3       ≥64     0.0    100    ≥64     0.0    95.7   \-      \-     \-     ≥64     0.0    100    \-      \-     \-     ≥64     1.2    92.9
                                 AMC        \-     \-     \-     16      72.7   27.3   1       100    0.0        2       100    0.0    1       100    0.0    \-      \-     \-     2       100    0.0    \-      \-     \-     2       96.4   3.6
                                 TZP        \-     \-     \-     1       90.9   9.1    0.25    100    0.0        ≤0.06   100    0.0    ≤0.06   100    0.0    \-      \-     \-     ≤0.06   100    0.0    \-      \-     \-     ≤0.06   98.8   1.2
                                 CRO        \-     \-     \-     1       100    NA     0.12    100    NA         0.12    100    NA     ≤0.06   100    NA     \-      \-     \-     ≤0.06   100    NA     \-      \-     \-     ≤0.06   100    NA
                                 FEP        \-     \-     \-     1       100    NA     ≤0.5    100    NA         ≤0.5    90.9   NA     ≤0.5    100    NA     \-      \-     \-     ≤0.5    100    NA     \-      \-     \-     ≤0.5    98.8   NA
                                 IPM        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     1       100    NA
                                 MEM        \-     \-     \-     \-      \-     \-     \-      \-     \-         0.12    100    NA     0.12    100    NA     \-      \-     \-     0.12    100    NA     \-      \-     \-     0.12    100    NA
                                 LVX        \-     \-     \-     0.12    100    NA     0.015   100    NA         0.03    100    NA     0.03    100    NA     \-      \-     \-     0.03    100    NA     \-      \-     \-     0.03    100    NA
                                 AMK        \-     \-     \-     8       NA     NA     8       NA     NA         8       NA     NA     8       NA     NA     \-      \-     \-     8       NA     NA     \-      \-     \-     8       NA     NA
                                 MIN        \-     \-     \-     2       90.9   0.0    ≤0.5    100    0.0        2       100    0.0    1       100    0.0    \-      \-     \-     1       100    0.0    \-      \-     \-     1       98.8   0.0
  ESBL-positive*K. oxytoca*      TGC        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     1       94.7   0.0
                                 AMP        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥64     0.0    100
                                 AMC        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥64     31.6   36.8
                                 TZP        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥256    47.4   47.4
                                 CRO        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥128    10.5   89.5
                                 FEP        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥64     73.7   15.8
                                 MEM        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     0.5     100    0.0
                                 LVX        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥16     52.6   36.8
                                 AMK        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     8       94.7   5.3
                                 MIN        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥32     68.4   10.5
  ESBL-positive*K. pneumoniae*   TGC        2      96.3   0.0    2       100    0.0    4       84.4   6.3        2       100    0.0    4       86.6   6.1    2       97.6   2.4    2       91.8   0.0    2       100    0.0    2       92.9   2.4
                                 AMP        ≥64    0.0    100    ≥64     0.0    100    ≥64     0.0    100        ≥64     0.0    100    ≥64     0.0    98.8   ≥64     0.0    100    ≥64     1.4    97.3   ≥64     0.0    100    ≥64     0.3    99.1
                                 AMC        ≥64    37.0   29.6   ≥64     27.8   44.4   ≥64     12.5   59.4       32      15.2   45.5   32      23.2   40.2   ≥64     14.3   61.9   ≥64     16.4   50.7   ≥64     34.5   31.0   ≥64     21.1   46.1
                                 TZP        ≥256   51.9   33.3   128     38.9   16.7   ≥256    28.1   62.5       ≥256    33.3   57.6   ≥256    39.0   45.1   ≥256    21.4   59.5   ≥256    32.9   50.7   ≥256    58.6   31.0   ≥256    36.6   47.3
                                 CRO        ≥128   3.7    96.3   ≥128    0.0    94.4   ≥128    3.1    90.6       ≥128    0.0    100    ≥128    0.0    100    ≥128    0.0    100    ≥128    8.2    91.8   64      3.4    93.1   ≥128    2.7    96.1
                                 FEP        ≥64    66.7   22.2   ≥64     50.0   33.3   ≥64     31.3   50.0       ≥64     27.3   63.6   ≥64     26.8   68.3   ≥64     21.4   71.4   ≥64     27.4   69.9   ≥64     55.2   31.0   ≥64     33.6   58.0
                                 IPM        0.5    100    0.0    0.5     100    0.0    2       55.0   0.0        \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     2       86.2   0.0
                                 MEM        \-     \-     \-     \-      \-     \-     0.25    100    0.0        2       60.6   6.1    2       82.9   4.9    4       69.0   11.9   2       87.7   2.7    1       93.1   3.4    2       81.2   5.2
                                 LVX        ≥16    55.6   25.9   ≥16     44.4   50.0   ≥16     40.6   59.4       ≥16     30.3   66.7   ≥16     26.8   67.1   ≥16     16.7   81.0   ≥16     31.5   65.8   ≥16     37.9   55.2   ≥16     32.4   62.5
                                 AMK        32     81.5   0.0    ≥128    72.2   27.8   ≥128    68.8   31.3       ≥128    72.7   27.3   ≥128    69.5   29.3   ≥128    71.4   23.8   ≥128    78.1   20.5   16      93.1   3.4    ≥128    75.0   22.0
                                 MIN        16     59.3   25.9   ≥32     50.0   38.9   ≥32     34.4   59.4       ≥32     60.6   33.3   ≥32     36.6   56.1   ≥32     45.2   35.7   ≥32     30.1   49.3   ≥32     69.0   17.2   ≥32     43.8   43.5
  VR *E. faecalis*               TGC        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     0.25    100    NA
                                 AMP        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     4       100    0.0
                                 PEN        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     8       100    0.0
                                 AMC        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     2       NA     NA
                                 TZP        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     16      NA     NA
                                 CRO        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥128    NA     NA
                                 MEM        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     16      NA     NA
                                 LVX        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥64     0.0    92.3
                                 MIN        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥16     19.2   30.8
                                 LZD        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     2       100    0.0
  VR *E. faecium*                TGC        \-     \-     \-     \-      \-     \-     0.12    100    NA         \-      \-     \-     1       78.6   NA     \-      \-     \-     \-      \-     \-     \-      \-     \-     0.12    94.5   NA
                                 AMP        \-     \-     \-     \-      \-     \-     ≥32     0.0    100        \-      \-     \-     ≥32     0.0    100    \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥32     5.5    94.5
                                 PEN        \-     \-     \-     \-      \-     \-     ≥16     0.0    100        \-      \-     \-     ≥16     7.1    92.9   \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥16     5.5    94.5
                                 AMC        \-     \-     \-     \-      \-     \-     ≥16     NA     NA         \-      \-     \-     ≥16     NA     NA     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥16     NA     NA
                                 TZP        \-     \-     \-     \-      \-     \-     ≥32     NA     NA         \-      \-     \-     ≥32     NA     NA     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥32     NA     NA
                                 CRO        \-     \-     \-     \-      \-     \-     ≥128    NA     NA         \-      \-     \-     ≥128    NA     NA     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥128    NA     NA
                                 IPM        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥32     NA     NA
                                 MEM        \-     \-     \-     \-      \-     \-     ≥32     NA     NA         \-      \-     \-     ≥32     NA     NA     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥32     NA     NA
                                 LVX        \-     \-     \-     \-      \-     \-     ≥64     0.0    100        \-      \-     \-     ≥64     0.0    100    \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥64     1.8    98.2
                                 MIN        \-     \-     \-     \-      \-     \-     ≥16     84.2   10.5       \-      \-     \-     ≥16     71.4   21.4   \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥16     70.9   21.8
                                 LZD        \-     \-     \-     \-      \-     \-     2       100    0.0        \-      \-     \-     2       92.9   7.1    \-      \-     \-     \-      \-     \-     \-      \-     \-     2       96.4   1.8
  MRSA                           TGC        0.25   100    NA     0.12    100    NA     0.25    100    NA         0.25    100    NA     0.25    100    NA     0.5     100    NA     0.25    100    NA     0.5     100    NA     0.25    100    NA
                                 AMP        ≥32    0.0    100    ≥32     0.0    100    ≥32     0.0    100        ≥32     0.0    100    ≥32     0.0    100    ≥32     0.0    100    ≥32     0.0    100    ≥32     0.0    100    ≥32     0.0    100
                                 PEN        ≥16    0.0    100    ≥16     0.0    100    ≥16     0.0    100        ≥16     0.0    100    ≥16     0.0    100    ≥16     0.0    100    ≥16     0.0    100    ≥16     0.0    100    ≥16     0.0    100
                                 AMC        ≥16    9.8    90.2   ≥16     11.6   88.4   ≥16     20.8   79.2       ≥16     26.9   73.1   ≥16     24.2   75.8   ≥16     16.7   83.3   ≥16     4.9    95.1   ≥16     3.9    96.1   ≥16     15.1   84.9
                                 TZP        ≥32    17.1   82.9   ≥32     16.3   83.7   ≥32     27.8   72.2       ≥32     30.8   69.2   ≥32     32.0   68.0   ≥32     25.8   74.2   ≥32     39.8   60.2   ≥32     19.5   80.5   ≥32     28.2   71.8
                                 CRO        ≥128   4.9    87.8   ≥128    7.0    86.0   ≥128    6.9    66.7       ≥128    17.3   67.3   ≥128    5.5    62.5   ≥128    6.1    71.2   ≥128    9.7    56.3   ≥128    5.2    77.9   ≥128    7.6    68.9
                                 IPM        ≥32    32.4   67.6   ≥32     8.6    91.4   ≥32     26.3   73.7       \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     \-      \-     \-     ≥32     22.0   78.0
                                 MEM        \-     \-     \-     \-      \-     \-     ≥32     43.4   52.8       ≥32     40.4   53.8   ≥32     52.3   41.4   ≥32     42.4   43.9   ≥32     54.4   30.1   ≥32     24.7   62.3   ≥32     44.8   45.4
                                 LVX        16     12.2   85.4   ≥64     4.7    93.0   32      1.4    97.2       32      3.8    96.2   ≥64     11.7   87.5   32      4.5    95.5   ≥64     5.8    92.2   ≥64     5.2    93.5   ≥64     6.5    92.3
                                 MIN        4      100    0.0    ≤0.25   100    0.0    1       97.2   1.4        0.5     94.2   1.9    2       96.9   0.0    2       97.0   1.5    1       96.1   0.0    2       97.4   1.3    2       97.1   0.7
                                 LZD        4      100    0.0    2       100    0.0    4       100    0.0        2       100    0.0    2       100    0.0    2       100    0.0    2       100    0.0    2       100    0.0    2       100    0.0
                                 VAN        2      100    0.0    1       100    0.0    2       100    0.0        1       100    0.0    1       100    0.0    1       100    0.0    2       100    0.0    1       100    0.0    2       100    0.0
  Pen-R *S. pneumoniae*          TGC        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     0.03    100    NA     0.03    100    NA     0.03    100    NA     \-      \-     \-     0.03    100    NA
                                 AMP        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     8       NA     NA     8       NA     NA     16      NA     NA     \-      \-     \-     8       NA     NA
                                 AMC        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     8       54.5   27.3   8       60.0   20.0   8       46.2   23.1   \-      \-     \-     8       60.0   20.0
                                 TZP        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     8       NA     NA     8       NA     NA     8       NA     NA     \-      \-     \-     8       NA     NA
                                 AZM        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     ≥128    18.2   81.8   64      30.0   70.0   ≥128    23.1   76.9   \-      \-     \-     ≥128    34.7   65.3
                                 CLR        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     ≥128    18.2   81.8   64      30.0   70.0   ≥128    23.1   76.9   \-      \-     \-     ≥128    34.7   65.3
                                 ERY        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     ≥128    18.2   81.8   64      30.0   70.0   ≥128    23.1   76.9   \-      \-     \-     ≥128    34.7   65.3
                                 CLI        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     ≥128    18.2   81.8   64      60.0   30.0   ≥128    46.2   53.8   \-      \-     \-     ≥128    49.0   49.0
                                 CRO        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     8       36.4   27.3   2       30.0   10.0   2       53.8   0.0    \-      \-     \-     2       54.0   10.0
                                 MEM        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     1       0.0    63.6   1       0.0    60.0   1       15.4   46.2   \-      \-     \-     1       4.2    62.5
                                 LVX        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     2       90.9   0.0    1       100    0.0    1       100    0.0    \-      \-     \-     2       96.0   2.0
                                 MIN        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     ≥16     9.0    54.5   8       70.0   30.0   ≥16     23.1   76.9   \-      \-     \-     ≥16     46.0   42.0
                                 LZD        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     1       100    NA     1       100    NA     1       100    NA     \-      \-     \-     1       100    NA
                                 VAN        \-     \-     \-     \-      \-     \-     \-      \-     \-         \-      \-     \-     0.5     100    NA     1       100    NA     0.5     100    NA     \-      \-     \-     1       100    NA

^a^ AMC = amoxicillin-clavulanate; AMP = ampicillin; AZM = azithromycin; CRO = ceftriaxone; CLR = clarithromycin; CLI = clindamycin; ERY = erythromycin; IPM = imipenem; LVX = levofloxacin; LZD = linezolid; MEM = meropenem; MIN = minocycline; PEN = penicillin; TZP = piperacillin-tazobactam; TGC = tigecycline; VAN = vancomycin. NA = susceptibility or resistance breakpoint not available. - MIC90, %S and %R are not given where N ≤10. No imipenem data was collected after 2006.

### 3.1.7. *P.* *aeruginosa*

Where breakpoints were available, *P. aeruginosa* had lower susceptibility than other Gram-negative pathogens to most T.E.S.T. agents ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}). This organism was most susceptible to amikacin (88.2% from 2004--2011); all other antimicrobial susceptibilities were between 54.6% (levofloxacin) and 64.1% (cefepime). *P. aeruginosa* isolates showed the highest levels of resistance to levofloxacin (39.1%) and the lowest levels to amikacin (6.6%) over all T.E.S.T. years. Breakpoints were not available for tigecycline and the activity of this agent was low against *P. aeruginosa* (MIC~90~ 16mg/L for all years combined). Two hundred and eighty MDR *P. aeruginosa* isolates were collected in Italy over all years of surveillance (19.1% of all *P. aeruginosa* isolates; [Table 4](#pharmaceuticals-06-01381-t004){ref-type="table"}). MDR *P. aeruginosa* showed high resistance (≥65.7%) to cefepime, ceftazidime, levofloxacin, meropenem and piperacillin-tazobactam; the lowest level of resistance was for amikacin (27.1%). A resistance rate of 25.1% to imipenem was reported among all *P. aeruginosa*; 100% of MDR *P. aeruginosa* isolates were resistant to imipenem ([Table 4](#pharmaceuticals-06-01381-t004){ref-type="table"}).

### 3.1.8. *S.* *marcescens*

The most effective antimicrobials against this organism were amikacin, cefepime, levofloxacin, meropenem, piperacillin-tazobactam and tigecycline (\>90% mean susceptibility over 2004--2011; [Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}). Of these agents, isolates of *S. marcescens* were least resistant to amikacin and tigecycline (\<1% overall resistance). Ceftriaxone susceptibility was lowest in 2004 (64.3%) and peaked at 94.0% in 2007. Imipenem susceptibility was observed among 85.7% of *S. marcescens* isolates ([Table 2](#pharmaceuticals-06-01381-t002){ref-type="table"}).

3.2. Gram-Positive Isolates
---------------------------

Over all T.E.S.T. years in Italy, the Gram-positive organisms collected, in order of highest to lowest importance, were *S. aureus* (42.1%), *E. faecalis* (18.1%), *S. pneumoniae* (16.5%), *S. agalactiae* (15.0%) and *E. faecium* (8.2%; [Table 1](#pharmaceuticals-06-01381-t001){ref-type="table"}). Generally speaking, tigecycline, linezolid, vancomycin and the carbapenems were active against the majority of Gram-positive isolates in this study.

### 3.2.1. *E.* *faecalis*

Over all T.E.S.T. years, isolates were \>90% susceptible to ampicillin, linezolid, penicillin, tigecycline and vancomycin, and least susceptible to minocycline (25.3%; [Table 3](#pharmaceuticals-06-01381-t003){ref-type="table"}). The highest resistance from 2004--2011 was to minocycline (38.5%) and levofloxacin (33.2%). No linezolid-resistant isolates were collected over the study period. Only 0.4% of isolates were resistant to ampicillin or penicillin; all these resistant isolates were collected in 2010. Vancomycin-resistant *E. faecalis* were most prevalent in 2004 (18.8%), after which time the proportions of resistant isolates decreased, down to 0% in 2011 ([Table 5](#pharmaceuticals-06-01381-t005){ref-type="table"}). All vancomycin-resistant *E. faecalis* isolates were susceptible to tigecycline, ampicillin, penicillin and linezolid ([Table 6](#pharmaceuticals-06-01381-t006){ref-type="table"}).

### 3.2.2. *E.* *faecium*

During the T.E.S.T. study, the most effective agents against this pathogen were linezolid and tigecycline (\>98% susceptibility; [Table 3](#pharmaceuticals-06-01381-t003){ref-type="table"}). Two linezolid-resistant isolates were collected in 2008 (1.9%), resulting in a 0.6% resistance rate over the total study period. Overall, *E. faecium* isolates from Italy were least susceptible (12.5%) and most resistant (83.0%) to levofloxacin. Resistance to ampicillin, penicillin and vancomycin increased from 2004 to 2006 to a maximum of 90.0%, 92.5% and 47.5%, respectively. From 2006 onwards, however, resistance to these three antimicrobials decreased, giving overall resistance values of 79.8%, 70.5% and 16.4%, respectively. The frequency of vancomycin-resistant isolates of *E. faecium* increased from 18.2% in 2004 to a maximum of 47.5% in 2006 but then decreased to 0.0% in 2011 ([Table 5](#pharmaceuticals-06-01381-t005){ref-type="table"}). High susceptibility to linezolid (96.4%) and tigecycline (94.5%) was noted among vancomycin-resistant *E. faecium* isolates ([Table 6](#pharmaceuticals-06-01381-t006){ref-type="table"}).

### 3.2.3. *S.* *agalactiae*

*S. agalactiae* were \>97% susceptible to most agents (ampicillin, ceftriaxone, levofloxacin, linezolid, meropenem, penicillin, tigecycline and vancomycin) in every T.E.S.T. year ([Table 3](#pharmaceuticals-06-01381-t003){ref-type="table"}). Low susceptibility and high resistance were reported only to minocycline (19.0% and 74.3%, respectively).

### 3.2.4. *S.* *aureus*

*S. aureus* were 100% susceptible to linezolid, tigecycline and vancomycin in every year of surveillance in Italy ([Table 3](#pharmaceuticals-06-01381-t003){ref-type="table"}). No isolates were resistant to linezolid or vancomycin throughout T.E.S.T. *S. aureus* were 81.3% and 97.9% susceptible to meropenem and minocycline, respectively, from 2004--2011, but whereas overall resistance to minocycline was \<1%, meropenem resistance was 15.4%. This pathogen only had high resistance to ampicillin and penicillin (82.3% and 84.2% resistance, respectively, for all study years combined). Methicillin resistance was noted in 33.8% of isolates overall, with the annual frequencies of MRSA ranging from 27.8% in 2007 to 45.1% in 2004 ([Table 5](#pharmaceuticals-06-01381-t005){ref-type="table"}). All MRSA isolates were susceptible to tigecycline, linezolid and vancomycin, while 97.1% were susceptible to minocycline ([Table 6](#pharmaceuticals-06-01381-t006){ref-type="table"}).

### 3.2.5. *S.* *pneumoniae*

From 2004--2011, all isolates were susceptible to linezolid, tigecycline and vancomycin, and \>95% susceptibility was noted for ceftriaxone and levofloxacin ([Table 3](#pharmaceuticals-06-01381-t003){ref-type="table"}). *S. pneumoniae* were ≤5% resistant to all of the above agents, with the exception of meropenem (3.4%-11.8% resistance annually). Susceptibility to minocycline decreased from approximately 70--75% in 2004--2007 to between 26.7% and 55.2% annually over the period 2008 to 2011. Penicillin susceptibility ranged from 67.4% to 80.0% between 2004 and 2011. Azithromycin, clarithromycin and erythromycin had similar overall susceptibility (56--57%) and resistance (42.5--43.5%) values for *S. pneumoniae* ([Table 3](#pharmaceuticals-06-01381-t003){ref-type="table"}). *S. pneumoniae* was more susceptible (67%) and less resistant (32.9%) to clindamycin than to the macrolides between 2004--2011. Penicillin-resistant *S. pneumoniae* (PRSP) increased in prevalence from 4.9% in 2004 to 14.1% in 2010, but decreased to 3.4% in 2011 ([Table 5](#pharmaceuticals-06-01381-t005){ref-type="table"}). All PRSP isolates were tigecycline-, linezolid- and vancomycin-susceptible, while 96.0% were susceptible to levofloxacin ([Table 6](#pharmaceuticals-06-01381-t006){ref-type="table"}). Imipenem susceptibility was noted among 95.1% of *S. pneumoniae* isolates (2004--2006) ([Table 3](#pharmaceuticals-06-01381-t003){ref-type="table"}).

4. Discussion
=============

Tigecycline is licensed in Italy to treat complicated intra-abdominal and skin and soft tissue infections. Good clinical results for tigecycline have been demonstrated previously: for example, Bassetti *et al.* \[[@B11-pharmaceuticals-06-01381]\] showed a 76.5% (13/17) success rate for tigecycline in the treatment of complicated skin and soft tissue infections and an 82.8% (72/87) success rate against peritonitis. This clinical success is reflected by high tigecycline susceptibility for most pathogens over the course of the T.E.S.T. study between 2004 and 2011: Gram-negative pathogens showed \>94% tigecycline susceptibility while Gram-positives were \>98% susceptible in the present report.

The two Gram-negative organisms in this study for which tigecycline breakpoints were not available were *A. baumannii* and *P. aeruginosa*. Against *A. baumannii*, tigecycline had the lowest overall MIC~90~ (2 mg/L) of all T.E.S.T. agents in Italy. A previously published Italian surveillance study comprising nine hospitals also determined an MIC~90~ of 2 mg/L for tigecycline against *A. baumannii* isolates collected between 2003 and 2004 \[[@B12-pharmaceuticals-06-01381]\]. As in the current analysis, the one-year study found that *A. baumannii* isolates had low (≤51%) susceptibility to amikacin, cefepime, ceftazidime, meropenem and piperacillin-tazobactam. The proportion of *A. baumannii* resistant to piperacillin-tazobactam in the 2003--2004 study (44%) was lower than to the overall value in this T.E.S.T. paper (63.3%; 2004--2011). However, the 2003--2004 frequency of imipenem-resistant isolates (50%) was around 36% higher than T.E.S.T. (13.7%; 2004--2006). Both studies used CLSI methodologies to determine imipenem susceptibility, but there were 27 countrywide centres collecting isolates for T.E.S.T., compared with nine centres in the central-south region of Italy for the 2003--2004 study. The high incidence of imipenem resistance in the one-year study could, therefore, be due to a localised outbreak of imipenem-resistant *A. baumannii* infections in this region of Italy during 2003--2004. *A. baumannii* gained resistance to most antimicrobials on the panel over the course of the T.E.S.T. study in Italy as described in this report, and the greatest increase in resistance was to piperacillin-tazobactam (49.1% from 2004 to 2011). There were also \>40% increases in resistance to amikacin and levofloxacin.

Epidemiological studies of *A. baumannii* in Italy have focussed mostly on carbapenem-resistant or MDR isolates. Lambiase *et al.* \[[@B13-pharmaceuticals-06-01381]\] examined 567 *A. baumannii* isolates from an ICU in Naples between 2007 and 2010, and found that all isolates were MDR, including carbapenems; these isolates were clonal in nature, all possessing the *bla*~OXA-51-like~ and *bla*~OXA-58-like~ genes. D'Arezzo *et al.* \[[@B14-pharmaceuticals-06-01381]\] reported a high (60.5%) prevalence of elevated (MIC≥128 mg/L) resistance to imipenem among 111 *A. baumannii* isolates, associated with *bla*~OXA-58-like~ (22.8%) or *bla*~OXA-51-like~ (71.1%) genes. Most of these isolates (95.6%) were related to international clonal lineage II. In a study of six hospitals in Florence, Donnarumma *et al.* \[[@B15-pharmaceuticals-06-01381]\] showed three main clonal groups of *A. baumannii*, A1, A2 and A3; A1 was genetically related to the European EU II clone. All isolates possesses the *bla*~OXA-51-like~ gene, and 65% of these isolates were resistant to imipenem. As reported globally \[[@B16-pharmaceuticals-06-01381]\], clonal lineages appear to predominate among *A. baumannii* isolates in Italy, although there may be variation between different geographical areas.

In the 2003--2004 Italian study by Mezzatesta *et al.* \[[@B12-pharmaceuticals-06-01381]\], 49.5% of the 107 *A. baumannii* isolates tested were resistant to three antimicrobial classes (specifically fluoroquinolones, ceftazidime, and aminoglycosides or imipenem). This was only slightly lower than the proportion of MDR *A. baumannii* collected over the T.E.S.T. surveillance period in Italy (60%). In a separate study of seven centres in Rome carried out from 2004 to 2005, antimicrobial susceptibility was determined for 22 MDR *A. baumannii* patient isolates \[[@B17-pharmaceuticals-06-01381]\]. Of these 22 isolates, 21 (95.5%) were resistant to levofloxacin, 19 (86.4%) were resistant to piperacillin-tazobactam, and 14 (63.6%) were resistant to amikacin. The MDR *A. baumannii* isolates collected in T.E.S.T. were highly resistant to levofloxacin (98.1%), piperacillin-tazobactam (93.7%) and amikacin (87.5%) over all years of surveillance. In the seven-centre study by Principe *et al.* \[[@B17-pharmaceuticals-06-01381]\], three MDR *A. baumannii* isolates (13.6%) were resistant to tigecycline (using the FDA Enterobacteriaceae breakpoints for tigecycline \[S, ≤2 mg/L; R, ≥8 mg/L\]). A single Italian hospital also determined drug resistance among 50 MDR *A. baumannii* isolates collected between 2008 and 2009 \[[@B18-pharmaceuticals-06-01381]\]. Only 4% of these *A. baumannii* isolates were resistant to tigecycline (S, ≤2 mg/L; R, ≥8 mg/L). All isolates, however, were 100% resistant to imipenem, levofloxacin and piperacillin-tazobactam, and more than 90% resistant to amikacin, cefepime and ceftazidime. In this T.E.S.T. study, MDR *A. baumannii* isolates were highly resistant (\>79%) to the same antimicrobials, excluding imipenem (38.8%) and minocycline (5.1%).

Compared with *A. baumannii*, a lower overall proportion of MDR *P. aeruginosa* (19.1%) was recorded in Italy during T.E.S.T. In 2010, a similar percentage of invasive *P. aeruginosa* isolates from Italy (20.8%) was reported to have resistance to three or more antibiotic classes among aminoglycosides, carbapenems, ceftazidime, fluoroquinolones, and piperacillin-tazobactam \[[@B19-pharmaceuticals-06-01381]\]. The individual resistance values for ceftazidime and piperacillin-tazobactam against these invasive isolates were 21.2% and 17.7%, respectively, slightly lower than the 2010 T.E.S.T. results in Italy (32.9% resistance for both agents).

The highest proportion of resistant Gram-negative pathogens in the current Italian study was observed among ESBL-producing *E. coli* (24.8% from 2004--2011). This is a dramatic increase compared to the 10.8% occurrence of ESBL-positive *E. coli* isolates nationally in 1999 \[[@B20-pharmaceuticals-06-01381]\]. An Italian single-hospital surveillance report from 2004 to 2007 identified 23.5% of *E. coli* as ESBL producers \[[@B21-pharmaceuticals-06-01381]\]. A more recent (2009--2010) study of another Italian hospital found that the most frequently observed multidrug-resistant pathogen was ESBL-producing *E. coli* (18.6% of all multidrug-resistant isolates) \[[@B22-pharmaceuticals-06-01381]\]. These data are in line with the findings from the current T.E.S.T. manuscript.

ESBL production has been linked with third-generation cephalosporin resistance \[[@B23-pharmaceuticals-06-01381]\]. The T.E.S.T. data showed that the resistance of *E. coli* to ceftriaxone in Italy increased more than two-fold between 2007 and 2008, during which time the prevalence of ESBL-producing *E. coli* isolates almost doubled. In 2010, the ECDC annual report found that in one Italian centre, all 23 of the invasive *E. coli* isolates resistant to third-generation cephalosporins were ESBL-producers \[[@B19-pharmaceuticals-06-01381]\]. In a 2007--2008 single hospital study of 13 countries, including Italy, higher mortality rates and longer hospital stays were associated with third-generation cephalosporin-resistant *E. coli* bloodstream infections \[[@B24-pharmaceuticals-06-01381]\]. These findings suggest that *E. coli* resistance in Italy is increasing, possibly due to the spread of ESBL-positive strains.

High proportions of ESBL-producing *K. pneumoniae* were also measured during T.E.S.T. (24.1% over all years). ESBL production has been associated with reduced carbapenem susceptibility in *K. pneumoniae* due to a loss of bacterial membrane permeability in some ESBL-producing isolates \[[@B25-pharmaceuticals-06-01381]\]. The recent ECDC report noted an increase in carbapenem-resistant *K. pneumoniae*, from 1% in 2006 to 27% in 2011 \[[@B1-pharmaceuticals-06-01381]\]. Another recent Italian paper has also highlighted a rise in carbapenem (imipenem and/or meropenem) non-susceptibility (intermediate plus resistant isolates) in *K. pneumoniae*, from 2.2% to 19.4% between 2009 and 2012, respectively \[[@B26-pharmaceuticals-06-01381]\]. These results are supported by the current T.E.S.T. study, in which *K. pneumoniae* resistance to meropenem increased in Italy from 1.4% in 2006 to 14.4% in 2011.

Although Gram-positive organisms were wholly susceptible to tigecycline, certain pathogens had low susceptibility to other antimicrobials during this T.E.S.T. study. *E. faecium*, for example, showed 79.8% resistance to ampicillin over all years of Italian surveillance. Similarly, an earlier report documented 70% ampicillin resistance among 913 *E. faecium* isolates from 20 Italian centres between 1993 and 1995 \[[@B27-pharmaceuticals-06-01381]\]. The more recent report from a single Italian teaching hospital by Manfredi and Nanetti \[[@B21-pharmaceuticals-06-01381]\] also found that ampicillin had limited activity against *E. faecium* (7.5%-18.5% susceptibility in 175 isolates from 2004--2007). Vancomycin resistance in *E. faecium*, however, appears to be declining in Italy, as the ECDC reported 21% vancomycin-resistant isolates in 2004 but 4% in 2010 \[[@B19-pharmaceuticals-06-01381]\]. This T.E.S.T. study showed similar results in 2004 (18.2% vancomycin resistance), decreasing to 13.3% resistance in 2010, before a further decline to 0% in 2011. This reduction in vancomycin-resistant *E. faecium* may be related to increased use of infection-control strategies in hospitals, which have been shown to reduce the incidence of vancomycin-resistant enterococci \[[@B28-pharmaceuticals-06-01381]\].

The current T.E.S.T. data showed that 33.8% of *S. aureus* isolates in Italy were resistant to methicillin, increasing in prevalence between 2007 (27.8%) and 2011 (32.9%) (although an overall decrease was noted compared to 2004 \[45.1%\]). Similarly, the ECDC reported a small increase in the proportion of MRSA between 2007 and 2010, from 33% to 37% \[[@B19-pharmaceuticals-06-01381]\]. The distribution of MRSA across Italy is complicated. In Torino, characterization of 90 MRSA isolates revealed that most belonged to SCCmec types I and II \[[@B29-pharmaceuticals-06-01381]\], while in the Emilia-Romagna region, 63% of MRSA clones showed spa-types t008 or t041 \[[@B30-pharmaceuticals-06-01381]\]. An examination of 10 Panton-Valentine leukocidin-positive MRSA isolates from Bolzano province revealed a heterogeneous sample, with eight different ST clonal types identified \[[@B31-pharmaceuticals-06-01381]\]. Italy thus possesses a polyclonal population of MRSA, with different clonal types occurring in separate regions in differing proportions. Also, there has been a blurring of the distinction between community-acquired and hospital- acquired MRSA: one recent report has shown a high prevalence of the USA-300 clone in central Italy among both community- and hospital-acquired isolates of MRSA \[[@B32-pharmaceuticals-06-01381]\].

Two key antimicrobials in the treatment of infections caused by MRSA are vancomycin and linezolid. There have been numerous reports of increasing non-susceptibility to vancomycin among MRSA isolates in recent years \[[@B33-pharmaceuticals-06-01381]\]. However, there is no evidence of this in the current study in Italy: vancomycin retains 100% activity against *S. aureus* (and MRSA) through the T.E.S.T. study in 2004--2011. Vancomycin "MIC creep" appears to be a regional occurrence and not yet a generalized trend; medical institutions should thus regularly monitor local vancomycin susceptibility among MRSA isolates \[[@B34-pharmaceuticals-06-01381]\]. Similarly, linezolid has retained its normal good activity against *S. aureus* (and MRSA) in the current study, with 100% susceptibility reported over all study years. Linezolid has previously been shown to be active against vancomycin-intermediate isolates of MRSA collected in Italy, so is an important clinical tool in the fight against resistant infections \[[@B35-pharmaceuticals-06-01381]\].

Some important differences are observed when resistance rates in Italy are compared to global rates, as reported in Pfizer's online T.E.S.T. database \[[@B36-pharmaceuticals-06-01381]\]. In general, resistance levels to β-lactams (particularly ceftriaxone) and levofloxacin appear to be higher in Italy than globally. *A. baumannii* resistance to most antimicrobial agents is higher in Italy by approximately 15%, with the exceptions of amikacin and levofloxacin (resistance in Italy is \> 20% higher) as well as imipenem and minocycline (resistance is similar). *E. coli* resistance is also high in Italy: ampicillin and cefepime resistance are around 7% higher, while ceftriaxone and levofloxacin resistance are approximately 12% higher than globally. Among *Enterobacter* spp., resistance was roughly 10% higher in Italy to ceftriaxone, levofloxacin and piperacillin-tazobactam. Amoxicillin-clavulanate, cefepime, ceftriaxone, levofloxacin and piperacillin-tazobactam resistance among Italian isolates of *K. pneumoniae* are approximately 6--8% higher than isolates globally. Resistance is roughly 6--10% higher among isolates of *P. aeruginosa* from Italy to all antimicrobial agents (excluding amikacin, to which resistance is the same in Italy as globally). Among *S. pneumoniae*, macrolide, minocycline and clindamycin resistance are about 10%, 12% and 14% higher in Italy, respectively, while penicillin resistance is approximately 7% lower than the global average. Implementation of and strict adherence to resistance control measures, such as ongoing resistance surveillance, improved hand hygiene/increased glove use and/or the use of antimicrobial stewardship programs \[[@B37-pharmaceuticals-06-01381],[@B38-pharmaceuticals-06-01381]\], would almost certainly help to reduce the high levels of resistance observed in Italy.

The T.E.S.T. study, like all surveillance studies, suffers from inherent limitations. Although several centres participated in the T.E.S.T. study in Italy over 2004--2011, some contributed isolates over several years while others participated in a few years or even just one, causing fluctuations in isolate contribution both geographically and over time. Thus, regional variations in resistance in a given study year may have had a disproportionate influence on apparent national resistance levels.

Over all T.E.S.T. years, rates of β-lactamase-producing *H. influenzae*, ESBL-producing *K. oxytoca*, vancomycin-resistant *E. faecalis* and PRSP were ≤11.4% in Italy. Another encouraging result of this study was the identification of no vancomycin-resistant *Enterococci* in Italy in 2011. The above findings may indicate that these drug-resistant organisms are becoming less prevalent in Italian hospitals, and therefore, less of a threat to the welfare of patients. Other pathogens in Italy, including *E. coli* and *K. pneumoniae*, have shown increased resistance in recent years, due largely to the spread of ESBL-positive strains. Thus, these organisms must continue to be monitored for further changes in susceptibility in the future. The results of surveillance studies such as T.E.S.T. help members of the healthcare industry to monitor rates of *in vitro* susceptibility among important pathogens to widely used antimicrobial agents, both globally and regionally.

5. Conclusions
==============

Tigecycline and linezolid exhibited very good activity against Gram-positive pathogens in Italy, with MIC~90~s ranging from 0.06 to 0.25 mg/L and 1--4 mg/L, respectively. Vancomycin and the carbapenems also showed good activity against select Gram-positive pathogens. Tigecycline was the most active agent against Gram-negative pathogens (with the exception of *P. aeruginosa*), with MIC~90~s between 0.25 and 2 mg/L (but 16 mg/L for *P. aeruginosa*), while amikacin and the carbapenems also possessed good activity against many Gram-negative pathogens. Linezolid, tigecycline and vancomycin susceptibility were stable over the course of this study, but ampicillin, piperacillin-tazobactam, ceftriaxone and levofloxacin susceptibility varied by pathogen; minocycline and cefepime susceptibility decreased among several pathogens. ESBL-positive *E. coli* increased while ESBL-positive *Klebsiella* spp., vancomycin-resistant enterococci and MRSA decreased in prevalence during this study.
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